US20220008417A1 - Combinations of a pyrimidine containing nnrti with rt inhibitors - Google Patents
Combinations of a pyrimidine containing nnrti with rt inhibitors Download PDFInfo
- Publication number
- US20220008417A1 US20220008417A1 US17/472,870 US202117472870A US2022008417A1 US 20220008417 A1 US20220008417 A1 US 20220008417A1 US 202117472870 A US202117472870 A US 202117472870A US 2022008417 A1 US2022008417 A1 US 2022008417A1
- Authority
- US
- United States
- Prior art keywords
- amino
- reverse transcriptase
- tmc278
- cyanoethenyl
- dimethylphenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003112 inhibitor Substances 0.000 title claims description 48
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 title abstract description 3
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 claims abstract description 80
- 229940122313 Nucleoside reverse transcriptase inhibitor Drugs 0.000 claims abstract description 74
- YIBOMRUWOWDFLG-ONEGZZNKSA-N rilpivirine Chemical group CC1=CC(\C=C\C#N)=CC(C)=C1NC1=CC=NC(NC=2C=CC(=CC=2)C#N)=N1 YIBOMRUWOWDFLG-ONEGZZNKSA-N 0.000 claims description 110
- 150000003839 salts Chemical class 0.000 claims description 66
- 229940123527 Nucleotide reverse transcriptase inhibitor Drugs 0.000 claims description 38
- MCGSCOLBFJQGHM-SCZZXKLOSA-N abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 claims description 35
- 229960004748 abacavir Drugs 0.000 claims description 35
- XQSPYNMVSIKCOC-NTSWFWBYSA-N Emtricitabine Chemical compound C1=C(F)C(N)=NC(=O)N1[C@H]1O[C@@H](CO)SC1 XQSPYNMVSIKCOC-NTSWFWBYSA-N 0.000 claims description 30
- 239000008194 pharmaceutical composition Substances 0.000 claims description 26
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 claims description 25
- 229960001627 lamivudine Drugs 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 25
- 229960000366 emtricitabine Drugs 0.000 claims description 18
- 208000031886 HIV Infections Diseases 0.000 claims description 15
- YIBOMRUWOWDFLG-UHFFFAOYSA-N 4-[[4-[4-(2-cyanoethenyl)-2,6-dimethylanilino]pyrimidin-2-yl]amino]benzonitrile Chemical compound CC1=CC(C=CC#N)=CC(C)=C1NC1=CC=NC(NC=2C=CC(=CC=2)C#N)=N1 YIBOMRUWOWDFLG-UHFFFAOYSA-N 0.000 claims description 14
- 208000037357 HIV infectious disease Diseases 0.000 claims description 14
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims description 14
- 239000003937 drug carrier Substances 0.000 claims description 13
- 239000002552 dosage form Substances 0.000 claims description 6
- KZVVGZKAVZUACK-BJILWQEISA-N rilpivirine hydrochloride Chemical group Cl.CC1=CC(\C=C\C#N)=CC(C)=C1NC1=CC=NC(NC=2C=CC(=CC=2)C#N)=N1 KZVVGZKAVZUACK-BJILWQEISA-N 0.000 claims description 6
- LLYJISDUHFXOHK-GOCONZMPSA-N ferroptocide Chemical compound C[C@@H]1CC[C@@]23C[C@@H](C(=O)[C@]2([C@@]1([C@@H](C[C@H]([C@@H]3C)C4=CCN5C(=O)N(C(=O)N5C4)C6=CC=CC=C6)OC(=O)CCl)C)O)O LLYJISDUHFXOHK-GOCONZMPSA-N 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 abstract description 11
- 230000005540 biological transmission Effects 0.000 abstract description 8
- 238000011282 treatment Methods 0.000 abstract description 7
- 239000002773 nucleotide Substances 0.000 abstract description 6
- 125000003729 nucleotide group Chemical group 0.000 abstract description 6
- 230000002265 prevention Effects 0.000 abstract description 6
- 239000002726 nonnucleoside reverse transcriptase inhibitor Substances 0.000 abstract description 5
- 241000725303 Human immunodeficiency virus Species 0.000 description 77
- 239000000651 prodrug Substances 0.000 description 57
- 229940002612 prodrug Drugs 0.000 description 57
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 description 49
- 239000003814 drug Substances 0.000 description 35
- 229940079593 drug Drugs 0.000 description 32
- 150000001875 compounds Chemical class 0.000 description 31
- 229960004556 tenofovir Drugs 0.000 description 29
- 239000004480 active ingredient Substances 0.000 description 27
- 241000700605 Viruses Species 0.000 description 22
- 239000000203 mixture Substances 0.000 description 21
- 102100034343 Integrase Human genes 0.000 description 20
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 20
- 230000035772 mutation Effects 0.000 description 19
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 18
- 230000000840 anti-viral effect Effects 0.000 description 17
- 229960004693 tenofovir disoproxil fumarate Drugs 0.000 description 17
- WMHSRBZIJNQHKT-FFKFEZPRSA-N abacavir sulfate Chemical compound OS(O)(=O)=O.C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1.C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 WMHSRBZIJNQHKT-FFKFEZPRSA-N 0.000 description 15
- 230000000798 anti-retroviral effect Effects 0.000 description 15
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 15
- NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 description 14
- 229960002555 zidovudine Drugs 0.000 description 14
- 229960000531 abacavir sulfate Drugs 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 13
- 238000002512 chemotherapy Methods 0.000 description 11
- 238000000338 in vitro Methods 0.000 description 11
- 239000000047 product Substances 0.000 description 10
- -1 RO-5-3335 Chemical compound 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 239000004599 antimicrobial Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 230000001568 sexual effect Effects 0.000 description 8
- 238000002560 therapeutic procedure Methods 0.000 description 7
- XPOQHMRABVBWPR-UHFFFAOYSA-N Efavirenz Natural products O1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(F)F)C#CC1CC1 XPOQHMRABVBWPR-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 229960003804 efavirenz Drugs 0.000 description 6
- XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 229960000689 nevirapine Drugs 0.000 description 6
- 239000002777 nucleoside Substances 0.000 description 6
- 239000007935 oral tablet Substances 0.000 description 6
- 230000036470 plasma concentration Effects 0.000 description 6
- 230000010076 replication Effects 0.000 description 6
- 230000003612 virological effect Effects 0.000 description 6
- 208000030507 AIDS Diseases 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 229940124522 antiretrovirals Drugs 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 229940096978 oral tablet Drugs 0.000 description 5
- 239000006187 pill Substances 0.000 description 5
- 238000002741 site-directed mutagenesis Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 241000282414 Homo sapiens Species 0.000 description 4
- XNKLLVCARDGLGL-JGVFFNPUSA-N Stavudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1C=C[C@@H](CO)O1 XNKLLVCARDGLGL-JGVFFNPUSA-N 0.000 description 4
- 239000000227 bioadhesive Substances 0.000 description 4
- 238000009093 first-line therapy Methods 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 229940042404 nucleoside and nucleotide reverse transcriptase inhibitor Drugs 0.000 description 4
- 150000003833 nucleoside derivatives Chemical class 0.000 description 4
- 229940023488 pill Drugs 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 210000001215 vagina Anatomy 0.000 description 4
- VERWQPYQDXWOGT-LVJNJWHOSA-N 4-amino-5-fluoro-1-[(2r,5s)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one;[[(2r)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethyl-(propan-2-yloxycarbonyloxymethoxy)phosphoryl]oxymethyl propan-2-yl carbonate;(e)-but-2-enedioic acid Chemical compound OC(=O)\C=C\C(O)=O.C1=C(F)C(N)=NC(=O)N1[C@H]1O[C@@H](CO)SC1.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VERWQPYQDXWOGT-LVJNJWHOSA-N 0.000 description 3
- BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- IACQCQDWSIQSRP-ZCFIWIBFSA-N [(2r)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethyl-[hydroxy(phosphonooxy)phosphoryl]oxyphosphinic acid Chemical compound N1=CN=C2N(C[C@@H](C)OCP(O)(=O)OP(O)(=O)OP(O)(O)=O)C=NC2=C1N IACQCQDWSIQSRP-ZCFIWIBFSA-N 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 210000000214 mouth Anatomy 0.000 description 3
- 229940127073 nucleoside analogue Drugs 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 210000000664 rectum Anatomy 0.000 description 3
- 230000029812 viral genome replication Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 206010001513 AIDS related complex Diseases 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 102220638483 Protein PML_K65R_mutation Human genes 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- UGWQMIXVUBLMAH-IVVFTGHFSA-N [(1s,4r)-4-[2-amino-6-(cyclopropylamino)purin-9-yl]cyclopent-2-en-1-yl]methanol;4-amino-1-[(2r,5s)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1.C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 UGWQMIXVUBLMAH-IVVFTGHFSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000036436 anti-hiv Effects 0.000 description 2
- 238000011225 antiretroviral therapy Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000003501 co-culture Methods 0.000 description 2
- WHBIGIKBNXZKFE-UHFFFAOYSA-N delavirdine Chemical compound CC(C)NC1=CC=CN=C1N1CCN(C(=O)C=2NC3=CC=C(NS(C)(=O)=O)C=C3C=2)CC1 WHBIGIKBNXZKFE-UHFFFAOYSA-N 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- XPPKVPWEQAFLFU-UHFFFAOYSA-N diphosphoric acid Chemical group OP(O)(=O)OP(O)(O)=O XPPKVPWEQAFLFU-UHFFFAOYSA-N 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- CJPLEFFCVDQQFZ-UHFFFAOYSA-N loviride Chemical compound CC(=O)C1=CC=C(C)C=C1NC(C(N)=O)C1=C(Cl)C=CC=C1Cl CJPLEFFCVDQQFZ-UHFFFAOYSA-N 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000009097 single-agent therapy Methods 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 229960001203 stavudine Drugs 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 230000009264 viral breakthrough Effects 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- BSFPWNBIKBSHRL-UHFFFAOYSA-N 2-(2,6-dichlorophenyl)-2-(2-nitroanilino)acetamide Chemical compound ClC=1C=CC=C(Cl)C=1C(C(=O)N)NC1=CC=CC=C1[N+]([O-])=O BSFPWNBIKBSHRL-UHFFFAOYSA-N 0.000 description 1
- ILAYIAGXTHKHNT-UHFFFAOYSA-N 4-[4-(2,4,6-trimethyl-phenylamino)-pyrimidin-2-ylamino]-benzonitrile Chemical compound CC1=CC(C)=CC(C)=C1NC1=CC=NC(NC=2C=CC(=CC=2)C#N)=N1 ILAYIAGXTHKHNT-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- YIBOMRUWOWDFLG-ARJAWSKDSA-N 4-[[4-[4-[(z)-2-cyanoethenyl]-2,6-dimethylanilino]pyrimidin-2-yl]amino]benzonitrile Chemical compound CC1=CC(\C=C/C#N)=CC(C)=C1NC1=CC=NC(NC=2C=CC(=CC=2)C#N)=N1 YIBOMRUWOWDFLG-ARJAWSKDSA-N 0.000 description 1
- LHCOVOKZWQYODM-CPEOKENHSA-N 4-amino-1-[(2r,5s)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one;1-[(2r,4s,5s)-4-azido-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1.O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 LHCOVOKZWQYODM-CPEOKENHSA-N 0.000 description 1
- JTEGQNOMFQHVDC-RQJHMYQMSA-N 4-amino-1-[(2s,5r)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)SC1 JTEGQNOMFQHVDC-RQJHMYQMSA-N 0.000 description 1
- ZNFFMCYSMBXZQU-NSHDSACASA-N 5-chloro-8-methyl-7-(3-methyl-but-2-enyl)-6,7,8,9-tetrahydro-2h-2,7,9a-triaza-benzo[cd]azulene-1-thione Chemical compound C1N(CC=C(C)C)[C@@H](C)CN2C(=S)NC3=CC=C(Cl)C1=C32 ZNFFMCYSMBXZQU-NSHDSACASA-N 0.000 description 1
- 229940124321 AIDS medicine Drugs 0.000 description 1
- 102000002281 Adenylate kinase Human genes 0.000 description 1
- 108020000543 Adenylate kinase Proteins 0.000 description 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- AXRYRYVKAWYZBR-UHFFFAOYSA-N Atazanavir Natural products C=1C=C(C=2N=CC=CC=2)C=CC=1CN(NC(=O)C(NC(=O)OC)C(C)(C)C)CC(O)C(NC(=O)C(NC(=O)OC)C(C)(C)C)CC1=CC=CC=C1 AXRYRYVKAWYZBR-UHFFFAOYSA-N 0.000 description 1
- 108010019625 Atazanavir Sulfate Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- QAGYKUNXZHXKMR-UHFFFAOYSA-N CPD000469186 Natural products CC1=C(O)C=CC=C1C(=O)NC(C(O)CN1C(CC2CCCCC2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-UHFFFAOYSA-N 0.000 description 1
- JDVVGAQPNNXQDW-WCMLQCRESA-N Castanospermine Natural products O[C@H]1[C@@H](O)[C@H]2[C@@H](O)CCN2C[C@H]1O JDVVGAQPNNXQDW-WCMLQCRESA-N 0.000 description 1
- JDVVGAQPNNXQDW-TVNFTVLESA-N Castinospermine Chemical compound C1[C@H](O)[C@@H](O)[C@H](O)[C@H]2[C@@H](O)CCN21 JDVVGAQPNNXQDW-TVNFTVLESA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108010078851 HIV Reverse Transcriptase Proteins 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- KJHKTHWMRKYKJE-SUGCFTRWSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O KJHKTHWMRKYKJE-SUGCFTRWSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- AXDLCFOOGCNDST-UHFFFAOYSA-N N-methyl-DL-tyrosine Natural products CNC(C(O)=O)CC1=CC=C(O)C=C1 AXDLCFOOGCNDST-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 102000013901 Nucleoside diphosphate kinase Human genes 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 101150104269 RT gene Proteins 0.000 description 1
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 241000713311 Simian immunodeficiency virus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 102400000160 Thymopentin Human genes 0.000 description 1
- 101800001703 Thymopentin Proteins 0.000 description 1
- 101710100179 UMP-CMP kinase Proteins 0.000 description 1
- 101710119674 UMP-CMP kinase 2, mitochondrial Proteins 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 description 1
- BINXAIIXOUQUKC-UIPNDDLNSA-N [(3as,4r,6ar)-2,3,3a,4,5,6a-hexahydrofuro[2,3-b]furan-4-yl] n-[(2s,3r)-3-hydroxy-4-[(4-methoxyphenyl)sulfonyl-(2-methylpropyl)amino]-1-phenylbutan-2-yl]carbamate Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(CC(C)C)C[C@@H](O)[C@@H](NC(=O)O[C@@H]1[C@@H]2CCO[C@@H]2OC1)CC1=CC=CC=C1 BINXAIIXOUQUKC-UIPNDDLNSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine group Chemical group [C@@H]1([C@H](O)[C@H](O)[C@@H](CO)O1)N1C=NC=2C(N)=NC=NC12 OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229960001830 amprenavir Drugs 0.000 description 1
- YMARZQAQMVYCKC-OEMFJLHTSA-N amprenavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 YMARZQAQMVYCKC-OEMFJLHTSA-N 0.000 description 1
- 239000002259 anti human immunodeficiency virus agent Substances 0.000 description 1
- 239000003903 antiretrovirus agent Substances 0.000 description 1
- 229960003277 atazanavir Drugs 0.000 description 1
- AXRYRYVKAWYZBR-GASGPIRDSA-N atazanavir Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)[C@@H](O)CN(CC=1C=CC(=CC=1)C=1N=CC=CC=1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C1=CC=CC=C1 AXRYRYVKAWYZBR-GASGPIRDSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- 229960005319 delavirdine Drugs 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 229960002656 didanosine Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- PEASPLKKXBYDKL-FXEVSJAOSA-N enfuvirtide Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(C)=O)[C@@H](C)O)[C@@H](C)CC)C1=CN=CN1 PEASPLKKXBYDKL-FXEVSJAOSA-N 0.000 description 1
- 229960002049 etravirine Drugs 0.000 description 1
- PYGWGZALEOIKDF-UHFFFAOYSA-N etravirine Chemical compound CC1=CC(C#N)=CC(C)=C1OC1=NC(NC=2C=CC(=CC=2)C#N)=NC(N)=C1Br PYGWGZALEOIKDF-UHFFFAOYSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- MLBVMOWEQCZNCC-OEMFJLHTSA-N fosamprenavir Chemical compound C([C@@H]([C@H](OP(O)(O)=O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 MLBVMOWEQCZNCC-OEMFJLHTSA-N 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000004247 hand Anatomy 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 229960001936 indinavir Drugs 0.000 description 1
- CBVCZFGXHXORBI-PXQQMZJSSA-N indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 210000003535 interstitial dendritic cell Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 229960001021 lactose monohydrate Drugs 0.000 description 1
- 229940120937 lamivudine and abacavir Drugs 0.000 description 1
- 229940120920 lamivudine and tenofovir disoproxil Drugs 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229950006243 loviride Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 150000004712 monophosphates Chemical class 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000003643 myeloid progenitor cell Anatomy 0.000 description 1
- QAGYKUNXZHXKMR-HKWSIXNMSA-N nelfinavir Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-HKWSIXNMSA-N 0.000 description 1
- 229960000884 nelfinavir Drugs 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229940042402 non-nucleoside reverse transcriptase inhibitor Drugs 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- XDRYMKDFEDOLFX-UHFFFAOYSA-N pentamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 XDRYMKDFEDOLFX-UHFFFAOYSA-N 0.000 description 1
- 229960004448 pentamidine Drugs 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229960002169 plerixafor Drugs 0.000 description 1
- YIQPUIGJQJDJOS-UHFFFAOYSA-N plerixafor Chemical compound C=1C=C(CN2CCNCCCNCCNCCC2)C=CC=1CN1CCCNCCNCCCNCC1 YIQPUIGJQJDJOS-UHFFFAOYSA-N 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001566 pro-viral effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 229960000311 ritonavir Drugs 0.000 description 1
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 1
- 229960001852 saquinavir Drugs 0.000 description 1
- QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000005582 sexual transmission Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 description 1
- 229960005314 suramin Drugs 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000010648 susceptibility to HIV infection Diseases 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 229960004517 thymopentin Drugs 0.000 description 1
- PSWFFKRAVBDQEG-YGQNSOCVSA-N thymopentin Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 PSWFFKRAVBDQEG-YGQNSOCVSA-N 0.000 description 1
- ZFEAMMNVDPDEGE-LGRGJMMZSA-N tifuvirtide Chemical compound C([C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(C)=O)[C@@H](C)CC)[C@@H](C)O)[C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)C1=CC=C(O)C=C1 ZFEAMMNVDPDEGE-LGRGJMMZSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- YFNGWGVTFYSJHE-UHFFFAOYSA-K trisodium;phosphonoformate Chemical compound [Na+].[Na+].[Na+].OP(O)(=O)C([O-])=O.OP(O)(=O)C([O-])=O.OP(O)(=O)C([O-])=O YFNGWGVTFYSJHE-UHFFFAOYSA-K 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention concerns combinations of a pyrimidine containing NNRTI with nucleoside reverse transcriptase inhibitors and/or nucleotide reverse transcriptase inhibitors useful for the treatment of HIV infected patients or for the prevention of HIV transmission or infection.
- HAART therapy Highly Active Anti-Retroviral Therapy
- NRTIs nucleoside reverse transcriptase inhibitors
- NRTIs non-nucleoside reverse transcriptase inhibitors
- NtRTIs nucleotide reverse transcriptase inhibitors
- protease inhibitors and even the more recent fusion inhibitors is still a major cause of therapy failure.
- half of the patients receiving anti-HIV combination therapy do not respond fully to the treatment, mainly because of resistance of the virus to one or more drugs used.
- resistant virus is carried over to newly infected individuals, resulting in severely limited therapy options for these drug-naive patients.
- the pharmacokinetic profile of many commercially available antiretrovirals does not allow relatively low therapeutic doses. Poor pharmacokinetic profiles often in combination with poor solubility properties of the antiretrovirals cause the AIDS patient to face a high pill burden which is particularly undesirable for drug-na ⁇ ve patients or first line therapy. Moreover, as a consequence of the AIDS virus even resisting antiretroviral combination therapy, a physician will boost the plasma levels of the active drugs in order for said antiretrovirals to regain effectivity against the mutated HIV viruses, the consequence of which is an even higher increase in pill burden. Boosting plasma levels may also lead to an increased risk of non-compliance with the prescribed therapy and to increased side-effects.
- WO 93/23021 describes therapeutic combinations for the treatment of HIV-infections comprising zidovudine and an agent serving to enhance the antiviral activity against HIV populations otherwise resistant to zidovudine.
- WO 96/01110 describes a triple combination of zidovudine, lamivudine and loviride, the latter being a non-nucleoside RT inhibitor of the ⁇ -APA class.
- WO 03/016306 specifically discloses more than 250 pyrimidine derivative having HIV replication inhibiting properties that act as non-nucleoside RT inhibitors (NNRTIs) having the ability to inhibit the replication both wild-type and of mutant strains.
- NNRTIs non-nucleoside RT inhibitors
- One of said NNRTIs is 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]-amino]-2-pyrimidinyl]amino]-benzonitrile (herein referred to as TMC278).
- TMC278 non-nucleoside RT inhibitors
- WO 03/016306 also discloses the methods to synthesize these compounds. It further discloses combinations of said NNRTIs with other antiretrovirals, i.e.
- Another object of the invention is to provide combinations of more than one therapeutically active antiretroviral drug wherein each of the active antiretroviral drugs of the combinations can be administered once daily thus reducing the pill burden for the patient.
- a further object of the invention is to provide combinations of more than one therapeutically active antiretroviral drug wherein each of the active antiretroviral drugs of the combinations can be co-formulated.
- Yet a further object of the invention is to provide combinations of more that one therapeutically active antiretroviral drug wherein a therapeutically effective amount of each of the active antiretroviral drugs of the combinations can be co-formulated in one single pharmaceutical formulation.
- Another object of the present invention is to provide combinations of more than one active antiretroviral drug which combinations can be used to prevent HIV transmission or infection in humans.
- the present invention provides a combination comprising (i) TMC278 or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof; or a prodrug thereof; and (ii) a nucleoside reverse transcriptase inhibitor and/or a nucleotide reverse transcriptase inhibitor; wherein TMC278 and the nucleotide reverse transcriptase inhibitor and/or the nucleoside reverse transcriptase inhibitor are therapeutically effective HIV inhibitors at a dose that can be administered once daily.
- the present invention provides a combination comprising (i) TMC278 or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof; or a prodrug thereof; and (ii) a nucleoside reverse transcriptase inhibitor; wherein TMC278 and the nucleoside reverse transcriptase inhibitor are therapeutically effective HIV inhibitors at a dose that can be administered once daily.
- a combination comprising (i) TMC278 or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof; or a prodrug thereof; and (ii) a nucleotide reverse transcriptase inhibitor; wherein TMC278 and the nucleotide reverse transcriptase inhibitor are therapeutically effective HIV inhibitors at a dose that can be administered once daily.
- a triple combination comprising (i) TMC278 or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof; or a prodrug thereof; and (ii) a nucleoside reverse transcriptase inhibitor; and (iii) a nucleotide reverse transcriptase inhibitor; wherein TMC278 and the nucleotide reverse transcriptase inhibitor and the nucleoside reverse transcriptase inhibitor are therapeutically effective HIV inhibitors at a dose that can be administered once daily.
- a triple combination comprising (i) TMC278 or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof; or a prodrug thereof; and (ii) a nucleoside reverse transcriptase inhibitor; and (iii) a second nucleoside reverse transcriptase inhibitor different from the nucleoside reverse transcriptase inhibitor of (ii); wherein TMC278 and the first and second nucleoside reverse transcriptase inhibitors are therapeutically effective HIV inhibitors at a dose that can be administered once daily.
- a pharmaceutical formulation comprising a pharmaceutically acceptable carrier and a combination as specified herein.
- the invention also concerns the use of the combinations specified herein as HIV inhibitors and the use thereof in the treatment of HIV infected patients or in the prevention of HIV transmission or infection.
- TMC278 is a potent reverse transcriptase inhibitor that has an extremely high genetic barrier in combination with a favourable pharmacokinetic profile allowing once daily dosing. It was surprising to discover that TMC278 has all these properties together. This is unusual because one cannot predict what mutations will be selected in the HIV-1 genome by a given drug, whether the mutated virus will have any chance of survival under the pressure of the drug, how much drug is needed to limit or to suppress the recurrence of such mutated virus, and at what frequency such drug has to be given to maintain suppression of the development of a resistant virus that can break through the genetic barrier of the drug.
- the term ‘therapeutically effective HIV inhibitors at a dose that can be administered once daily’ means that the HIV inhibitors are suitable for dosing every 24 hours.
- the ‘term suitable for dosing every 24 hours’ means that the HIV inhibitors are such that they can be administered every 24 hours and give effective blood plasma concentrations of the active ingredients such that they are effective to suppress HIV infection over a period of 24 hours.
- the HIV inhibitors for use in the invention can be dosed every 24 hours.
- TMC278 or 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]-amino]-2-pyrimidinyl]-amino]-benzonitrile is a known NNRTI, which can be prepared as described in WO03/016306.
- TMC278 can be used in base form or, which is preferred, as a suitable pharmaceutically acceptable salt form, in particular as an acid addition salt form.
- the pharmaceutically acceptable addition salts are meant to comprise the therapeutically active non-toxic salt forms.
- the acid addition salt forms can be obtained by treating the base form with appropriate acids as inorganic acids, for example, hydrohalic acids, e.g.
- hydrochloric hydrobromic and the like; sulfuric acid; nitric acid; phosphoric acid and the like; or organic acids, for example, acetic, propanoic, hydroxyacetic, 2-hydroxy-propanoic, 2-oxopropanoic, oxalic, malonic, succinic, maleic, fumaric, malic, tartaric, 2-hydroxy-1,2,3-propanetricarboxylic, methanesulfonic, ethanesulfonic, benzene-sulfonic, 4-methylbenzenesulfonic, cyclohexanesulfamic, 2-hydroxybenzoic, 4-amino-2-hydroxybenzoic and the like acids.
- Preferred for use in the present invention are the hydrohalic acid salts, in particular the hydrochloride salt.
- TMC278 occurs in stereoisomeric forms, more in particular as E- and Z-isomeric forms. Both isomers may be used in the combinations of the present invention. Whenever reference is made herein to TMC278, the E- and the Z-form as well as any mixture of both forms are meant to be included.
- TMC278 for use in the invention is the E-isomer, i.e. (E)-4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]-amino]-2-pyrimidinyl]-amino]-benzonitrile (hereinafter called E-TMC278).
- E-TMC278 The Z-isomer of TMC278, i.e. (Z)-4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]-amino]-2-pyrimidinyl]-amino]-benzonitrile (hereinafter called compound Z-TMC278) can also be used. It has relatively high potency against wild-type HIV-1 but is less active against single and double mutants in comparison to the E-isomer. Table 1 shows the IC 50 value in nM of the E and Z-isomer of TMC278.
- E-TMC278 the pure E-isomer or any isomeric mixture of the E- and the Z-forms wherein the E-form is predominantly present is meant to be comprised, i.e. an isomeric mixture containing more than 50% or in particular more than 80% of the E-form, or even more than 90% of the E-form.
- E-form substantially free of the Z-form refers to E-Z-mixtures with no or almost no Z-form, e.g. isomeric mixtures containing as much as 90%, in particular 95% or even 98% or 99% of the E-form.
- the pure Z-isomer or any isomeric mixture of the Z- and the E-forms wherein the Z-form is predominantly present is meant to be comprised, i.e. an isomeric mixture containing more than 50% or in particular more than 80% of the Z-form, or even more than 90% of the Z-form.
- the Z-form substantially free of the E-form refers to E-Z-mixtures with no or almost no E-form, e.g. isomeric mixtures containing as much as 90%, in particular 95% or even 98% or 99% of the Z-form.
- salts of the isomeric forms of TMC278, in particular the salts mentioned above are also meant to be included for use in this invention.
- Z-TMC278 hydrochloride and specifically E-TMC278 hydrochloride are also meant to be included for use in this invention.
- the nucleotide reverse transcriptase inhibitor and the nucleoside reverse transcriptase inhibitor select mutations in the reverse transcriptase that do not cause resistance to TMC278.
- TMC278 and the nucleoside/nucleotide reverse transcriptase inhibitor or inhibitors are therapeutically effective HIV inhibitors at a dose that can be administered once daily and (2) the nucleoside/nucleotide reverse transcriptase inhibitor or inhibitors select mutations in the reverse transcriptase that do not cause resistance to TMC278.
- a combination comprising (i) TMC278 or its stereoisomeric form or pharmaceutically acceptable salt or its prodrug, and (ii) a nucleoside reverse transcriptase inhibitor, wherein (1) TMC278 and the nucleoside reverse transcriptase inhibitor are therapeutically effective HIV inhibitors at a dose that can be administered once daily and (2) the nucleoside reverse transcriptase inhibitor selects mutations in the reverse transcriptase that do not cause resistance to TMC278.
- a combination comprising (i) TMC278 or its stereoisomeric form or pharmaceutically acceptable salt or its prodrug, and (ii) a nucleotide reverse transcriptase inhibitor, wherein (1) TMC278 and the nucleotide reverse transcriptase inhibitor are therapeutically effective HIV inhibitors at a dose that can be administered once daily and (2) the nucleotide reverse transcriptase inhibitor selects mutations in the reverse transcriptase that do not cause resistance to TMC278.
- a triple combination comprising (i) TMC278 or its stereoisomeric form or pharmaceutically acceptable salt or its prodrug, and (ii) a nucleoside reverse transcriptase inhibitor, and (iii) a nucleotide reverse transcriptase inhibitor, wherein (1) TMC278 and the nucleotide reverse transcriptase inhibitor and the nucleoside reverse transcriptase inhibitor are therapeutically effective HIV inhibitors at a dose that can be administered once daily and (2) the nucleotide reverse transcriptase inhibitor and the nucleoside reverse transcriptase inhibitor select mutations in the reverse transcriptase that do not cause resistance to TMC278.
- a triple combination comprising (i) TMC278 or its stereoisomeric form or pharmaceutically acceptable salt or its prodrug, and (ii) a nucleoside reverse transcriptase inhibitor, and (iii) a second nucleoside reverse transcriptase inhibitor different from the nucleoside reverse transcriptase inhibitor of (ii); wherein (1) TMC278 and the nucleoside reverse transcriptase inhibitors are therapeutically effective HIV inhibitors at a dose that can be administered once daily and (2) the nucleoside reverse transcriptase inhibitors select mutations in the reverse transcriptase that do not cause resistance to TMC278.
- Preferred nucleotide reverse transcriptase inhibitors that can be used in the combinations subject of this invention include tenofovir and its prodrug tenofovir disoproxil fumarate.
- Tenofovir is an adenosine nucleotide analogue currently commercially available with activity against retroviruses.
- Tenofovir disoproxil fumarate (tenofovir DF) is a once-daily, orally administered prodrug of tenofovir.
- tenofovir DF needs to be hydrolysed to the ANP analogue and then phosphorylated to the active diphosphate moiety [Arimilli et al Antiviral Chemistry and Chemotherapy 1997, 8:6 (557-564); Fridland et al. Antiviral Research 1997, 34].
- the prodrug After entry in to lymphocytes or macrophages, the prodrug is quantitatively converted to the parent analogue, tenofovir, and phosphorylated to mono- and diphosphate metabolites.
- the cellular enzymes that are responsible for phosphorylation of this drug are adenylate kinase and nucleoside diphosphate kinase [Robbins et al. Antimicrobial Agents and Chemotherapy 1995, 39:10 (2304-2308); Robbins et al. Antimicrobial Agents and Chemotherapy 1998, 42:3 (612-617)].
- tenofovir is efficiently phosphorylated in resting as well as cycling peripheral blood lymphocytes [Robbins et al. 1998].
- Tenofovir can inhibit HIV-1 replication in different cell types that may target HIV, including primary human blood lymphocytes and macrophages [Perno et al. Antiviral Research 1992 (289-304); Perno et al. Molecular Pharmacology 1996, 50:2 (359-366)].
- the primary target of tenofovir diphosphate is reverse transcriptase (RT).
- Tenofovir diphosphate is a competitive inhibitor for the incorporation of deoxyadenosine triphosphate into nascent proviral DNA chains. Inhibition of HIV-1 RT by tenofovir diphosphate has an inhibition constant of approximately 0.9 ⁇ M, and if the analogue is incorporated into the growing viral DNA chain it may terminate further chain elongation. Tenofovir inhibits viral RT much more effectively than it inhibits cellular DNA polymerases [Suo et al Journal of Biological Chemistry 1998, 273:42 (2750-2758)]. The concentration required to inhibit the replication of various HIV-1 strains by 50% (EC50) in lymphocyte and macrophage cell types (MT-2, CEM, ACH8) ranges from 0.2 to 10 ⁇ M. The antiviral effect is achieved at non-toxic doses of tenofovir (selectivity index ranging from 100 to 2000). Tenofovir D F is currently available as 300 mg tablets to be taken once daily.
- a combination comprising (i) TMC278 or its stereoisomeric form or pharmaceutically acceptable salt or its prodrug, and (ii) tenofovir or its prodrug tenofovir disoproxil fumarate, wherein TMC278 and tenofovir or its prodrug tenofovir disoproxil fumarate are therapeutically effective HIV inhibitors at a dose that can be administered once daily.
- a triple combination comprising (i) TMC278 or its stereoisomeric form or pharmaceutically acceptable salt or its prodrug, and (ii) a nucleoside reverse transcriptase inhibitor, and (iii) tenofovir disoproxil fumarate; wherein TMC278 and the nucleoside reverse transcriptase inhibitor and tenofovir disoproxil fumarate are therapeutically effective HIV inhibitors at a dose that can be administered once daily.
- Preferred nucleoside reverse transcriptase inhibitors that can be used in the combinations of this invention include abacavir or a pharmaceutically acceptable salt thereof, emtricitabine, racemic FTC and lamivudine (also named 3TC).
- Emtricitabine or ( ⁇ )-FTC is the left ( ⁇ ) rotatory enantiomeric form of racemic FTC or (+)-cis-4-amino-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-2(1H)-pyrimidinone (FTC). It is a commercially available nucleoside analogue and exhibits activity against HIV-1 [Hoong et al. Journal of Organic Chemistry 1992 (5563-5565); Jeong et al Journal of Medicinal Chemistry 1993, 36:2 (181-195); Van Roey et al. Antiviral Chemistry and Chemotherapy 1993, 4:6 (369-375].
- the in vitro anti-HIV-1 activity of ( ⁇ )-beta-enantiomer of FTC was reported to be 20-fold more than the (+)-beta-enantiomer, and the (+)-enantiomer was significantly more toxic than the ( ⁇ )-enantiomer to myeloid progenitor cells [Schinazi et al Antimicrobial Agents and Chemotherapy 1992, 36:11 (2423-2431)].
- the potential for HIV-1 resistance to FTC was evaluated by serial passage of the virus in human PBMCs and MT-2 cells in the presence of increasing drug concentrations. Highly drug-resistant HIV-1 variants dominated the replicating virus population after two or more cycles of infection.
- RT derived from drug-resistant viral particles was 15- to 50-fold less susceptible to the 5′-triphosphate of FTC compared with the enzyme from parental drug susceptible virus.
- DNA sequence analysis of the RT gene amplified from resistant viruses consistently identified mutations at codon 184 from Met (ATG) to Val (GTG or GTA) [Schinazi et al Antimicrobial Agents and Chemotherapy 1993, 37:4 (875-881); Tisdale et al Antiviral Research 1993, 20:Suppl 1; Smith et al Journal of Virology 1997, 71:3 (2357-2362); Harrer et al Journal of Infectious Diseases 1996, 173:2 (476-479); Tisdale et al Proceedings of the National Academy of Sciences of the United States of America 1993, 90:12 (5653-5656)].
- ( ⁇ )-FTC is not suitable for monotherapy and needs to be administered in combination with other antiretroviral agents to effectively treat patients infected with HIV.
- Emtricitabine is available as 200 mg capsules to be taken once a day.
- Lamivudine has the chemical name ( ⁇ )-2′,3′-dideoxy-3′-thiacytidine and is described for instance in EP-382 526 as an antiviral nucleoside analogue. It is also a well established and useful antiretroviral which is commercially available for instance as 150 mg oral tablets. Lamivudine is also commercially available in combination with zidovudine (300 mg zidovudine/150 mg lamivudine), and in combination with lamivudine and abacavir sulfate (300 mg zidovudine/150 mg lamivudine/equivalent of 300 mg abacavir).
- Abacavir is a well established and useful antiretroviral which is commercially available for instance as an oral solution of abacavir sulfate in a strength equivalent to 20 mg abacavir base/ml, or as an oral tablet of abacavir sulfate in a strength equivalent to 300 mg abacavir base.
- Abacavir sulfate is also commercially available in combination with lamivudine and zidovudine (300 mg zidovudine/150 mg lamivudine/equivalent of 300 mg abacavir).
- Abacavir is a carbocyclic nucleoside with potent and selective anti-HIV activity.
- Abacavir in its optically active form is disclosed in EP-434 450.
- the cis-isomer of abacavir with unspecified absolute stereochemical configuration is described in EP-349 242.
- Abacavir is one of the most potent NRTI developed to date. An average reduction in viral load of more than 1.4 log 10 RNA copies/ml is observed after a short course of abacavir monotherapy. In vitro, resistant virus is not rapidly selected by abacavir. A significant decrease in susceptibility to abacavir in wild-type or zidovudine-resistant HIV-1 strains was not observed until after eight to ten passages in MT-4 cells.
- a set of resistance mutations at HIV reverse transcriptase (RT) codons, 65R, 74V, 115F and/or 184V, are selected during in vitro passage with abacavir, and a combination of these mutations was required to confer a 10-fold reduction in abacavir susceptibility in a laboratory strain of HIV.
- the first mutation detected upon passage of HIV-1 in an increasing concentration of abacavir is M184V, which confers only a 3-fold decrease in HIV-1 susceptibility.
- Phenotype resistance to 3TC and/or the presence of the 184V mutation does not prevent viral load response to abacavir therapy.
- a combination comprising (i) TMC278 or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof, or a prodrug thereof, and (ii) emtricitabine, wherein TMC278 and emtricitabine are therapeutically effective HIV inhibitors at a dose that can be administered once daily.
- a combination comprising (i) TMC278 or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof, or a prodrug thereof, and (ii) lamivudine, wherein TMC278 and lamivudine are therapeutically effective HIV inhibitors at a dose that can be administered once daily.
- a combination comprising (i) TMC278 or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof, or a prodrug thereof, and (ii) abacavir or a pharmaceutically acceptable salt thereof, characterized in that, TMC278 and abacavir are therapeutically effective HIV inhibitors at a dose that can be administered once daily.
- a combination comprising (i) TMC278 or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof, or a prodrug thereof, and (ii) abacavir sulfate, characterized in that, TMC278 and abacavir sulfate are therapeutically effective HIV inhibitors at a dose that can be administered once daily.
- a triple combination comprising (i) TMC278 or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof, or a prodrug thereof; and (ii) emtricitabine, and (iii) a nucleotide reverse transcriptase inhibitor, wherein TMC278 and the nucleotide reverse transcriptase inhibitor and emtricitabine are therapeutically effective HIV inhibitors at a dose that can be administered once daily.
- a triple combination comprising (i) TMC278 or or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof, or a prodrug thereof; and (ii) lamivudine, and (iii) a nucleotide reverse transcriptase inhibitor, wherein TMC278 and the nucleotide reverse transcriptase inhibitor and lamivudine are therapeutically effective HIV inhibitors at a dose that can be administered once daily.
- a triple combination comprising (i) TMC278 or or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof, or a prodrug thereof, and (ii) abacavir or a pharmaceutically acceptable salt thereof, or preferably abacavir sulfate, and (iii) a nucleotide reverse transcriptase inhibitor, wherein TMC278 and the nucleotide reverse transcriptase inhibitor and abacavir or a pharmaceutically acceptable salt thereof, or preferably abacavir sulphate, are therapeutically effective HIV inhibitors at a dose that can be administered once daily.
- a triple combination comprising (i) TMC278 or or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof, or a prodrug thereof; and (ii) emtricitabine, and (iii) tenofovir or its prodrug tenofovir disoproxil fumarate, wherein TMC278 and emtricitabine and tenofovir or its prodrug tenofovir disoproxil fumarate are therapeutically effective HIV inhibitors at a dose that can be administered once daily.
- a triple combination comprising (i) TMC278 or a stereoisomeric form thereof, or a pharmaceutically acceptable salt thereof, or a prodrug thereof, and (ii) lamivudine and (iii) tenofovir or its prodrug tenofovir disoproxil fumarate, wherein TMC278 and lamivudine and tenofovir or its prodrug tenofovir disoproxil fumarate are therapeutically effective HIV inhibitors at a dose that can be administered once daily.
- a triple combination comprising (i) TMC278 or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof; or a prodrug thereof; and (ii) abacavir or a pharmaceutically acceptable salt form thereof, preferably abacavir sulfate; and (iii) tenofovir or its prodrug tenofovir disoproxil fumarate, wherein TMC278 and abacavir or a pharmaceutically acceptable salt form thereof, preferably abacavir sulfate and tenofovir or its prodrug tenofovir disoproxil fumarate are therapeutically effective HIV inhibitors at a dose that can be administered once daily.
- the active ingredients in particular TMC278, emtricitabine, lamivudine, abacavir or a pharmaceutically acceptable salt form thereof, preferably abacavir sulfate, and tenofovir or its prodrug tenofovir disoproxil fumarate, are therapeutically effective HIV inhibitors at a dose that can be administered once daily.
- the double combinations of the present invention may contain one or more additional active ingredients, which can be agents useful for treating HIV infected patients or other active agents.
- the triple combinations of the present invention may equally contain one or more additional active ingredients, which can be agents useful for treating HIV infected patients or other active agents.
- any of these additional agents are therapeutically effective at a dose that can be administered once daily.
- the active ingredients of the combinations of the present invention may be administered simultaneously, concurrently or sequentially. Simultaneous administration may be done by employing a unitary pharmaceutical formulation or separate pharmaceutical formulations. In general, the combinations may be administered by topical, oral, rectal, intravenous, subcutaneous or intramuscular routes. For first line therapy of HIV infection, simultaneous administration employing a unitary pharmaceutical formulation is preferred.
- the invention also provides a product containing (i) TMC278 or a stereoisomeric form thereof, or a pharmaceutically acceptable salt thereof, or a prodrug thereof, and (ii) a nucleoside reverse transcriptase inhibitor and/or a nucleotide reverse transcriptase inhibitor; wherein TMC278 and the nucleotide reverse transcriptase inhibitor and/or the nucleoside reverse transcriptase inhibitor are therapeutically effective HIV inhibitors at a dose that can be administered once daily; as a combined preparation for simultaneous, separate or sequential use against HIV infection.
- a product containing (i) TMC278 or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof, or a prodrug thereof, and (ii) a nucleoside reverse transcriptase inhibitor; wherein TMC278 and the nucleoside reverse transcriptase inhibitor are therapeutically effective HIV inhibitors at a dose that can be administered once daily; as a combined preparation for simultaneous, separate or sequential use against HIV infection.
- a product containing (i) TMC278 or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof, or a prodrug thereof, and (ii) a nucleotide reverse transcriptase inhibitor, wherein TMC278 and the nucleotide reverse transcriptase inhibitor are therapeutically effective HIV inhibitors at a dose that can be administered once daily; as a combined preparation for simultaneous, separate or sequential use against HIV infection.
- a product containing (i) TMC278 or a stereoisomeric form thereof, or a pharmaceutically acceptable salt thereof, or a prodrug thereof; and (ii) a nucleoside reverse transcriptase inhibitor; and (iii) a nucleotide reverse transcriptase inhibitor; wherein TMC278 and the nucleotide reverse transcriptase inhibitor and the nucleoside reverse transcriptase inhibitor are therapeutically effective HIV inhibitors at a dose that can be administered once daily; as a combined preparation for simultaneous, separate or sequential use against HIV infection.
- a product containing (i) TMC278 or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof, or a prodrug thereof; and (ii) a nucleoside reverse transcriptase inhibitor; and (iii) a second nucleoside reverse transcriptase inhibitor other than the nucleoside reverse transcriptase inhibitor of (ii); wherein TMC278 and the nucleoside reverse transcriptase inhibitors are therapeutically effective HIV inhibitors at a dose that can be administered once daily; as a combined preparation for simultaneous, separate or sequential use against HIV infection.
- the active ingredients in the products of the invention are present in therapeutically effective amounts, the latter meaning an amount that is sufficient to exert a sufficient HIV inhibitory effect during a certain time period, i.e. the time period between each intake of the formulations, preferably for about 24 hours.
- Particular embodiments are products as specified above containing one or more of the specific active ingredients mentioned herein such as emtricitabine, racemic FTC, lamivudin, tenofovir and its prodrug tenofovir disoproxil fumarate.
- the products as mentioned above may contain separate formulations of the active ingredients, or two or where applicable more of the active ingredients may be co-formulated.
- the invention provides pharmaceutical formulations containing a combination as specified herein and a suitable carrier.
- a pharmaceutical formulation comprising a pharmaceutically acceptable carrier and as active ingredients (i) TMC278 or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof, or a prodrug thereof; and (ii) a nucleoside reverse transcriptase inhibitor and/or a nucleotide reverse transcriptase inhibitor; wherein TMC278 and the nucleoside reverse transcriptase inhibitor and/or the nucleotide reverse transcriptase inhibitor are therapeutically effective HIV inhibitors at a dose that can be administered once daily.
- the invention further provides a pharmaceutical formulation comprising a pharmaceutically acceptable carrier and as active ingredients (i) TMC278 or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof, or a prodrug thereof, and (ii) a nucleoside reverse transcriptase inhibitor; wherein TMC278 and the nucleoside reverse transcriptase inhibitor are therapeutically effective HIV inhibitors at a dose that can be administered once daily.
- a pharmaceutical formulation comprising a pharmaceutically acceptable carrier and as active ingredients (i) TMC278 or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof, or a prodrug thereof, and (ii) a nucleotide reverse transcriptase inhibitor, wherein TMC278 and the nucleoside reverse transcriptase inhibitor and the nucleotide reverse transcriptase inhibitor are therapeutically effective HIV inhibitors at a dose that can be administered once daily.
- a pharmaceutical formulation comprising a pharmaceutically acceptable carrier and as active ingredients (i) TMC278 or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof, or a prodrug thereof; and (ii) a nucleoside reverse transcriptase inhibitor; and (iii) a nucleotide reverse transcriptase inhibitor; wherein TMC278 and the nucleoside reverse transcriptase inhibitor and the nucleotide reverse transcriptase inhibitors are therapeutically effective HIV inhibitors at a dose that can be administered once daily.
- a pharmaceutical formulation comprising a pharmaceutically acceptable carrier and as active ingredients (i) TMC278 or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof, or a prodrug thereof; and (ii) a nucleoside reverse transcriptase inhibitor; and (iii) a second nucleoside reverse transcriptase inhibitor different from the nucleoside reverse transcriptase inhibitor of (ii); wherein TMC278 and the nucleoside reverse transcriptase inhibitors are therapeutically effective HIV inhibitors at a dose that can be administered once daily.
- the active ingredients in the pharmaceutical formulations of the invention are present in therapeutically effective amounts, the latter meaning an amount that is sufficient to exert a sufficient HIV inhibitory effect during a certain time period, i.e. the time period between each intake of the formulations, preferably for about 24 hours.
- Particular embodiments are pharmaceutical formulations as specified above containing one or more of the specific active ingredients mentioned herein such as emtricitabine, racemic FTC, lamivudin, tenofovir and its prodrug tenofovir disoproxil fumarate.
- the pharmaceutical formulations of the present invention may be formulated into various forms for different types of administration.
- effective amounts of the active ingredients optionally in addition salt form, is combined in intimate admixture with a pharmaceutically acceptable carrier, which carrier may take a wide variety of forms depending on the form of preparation desired for administration.
- a pharmaceutically acceptable carrier which carrier may take a wide variety of forms depending on the form of preparation desired for administration.
- the pharmaceutical formulations of the invention are preferably formulated in unitary dosage form suitable, particularly, for administration orally, rectally, percutaneously, or by parenteral injection.
- any of the usual pharmaceutical media may be employed such as, for example, water, glycols, oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs, emulsions and solutions; or solid carriers such as starches, sugars, kaolin, diluents, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules, and tablets. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit forms, in which case solid pharmaceutical carriers are obviously employed.
- the carrier will usually comprise sterile water, at least in large part, though other ingredients, for example, to aid solubility, may be included.
- injectable solutions for example, may be prepared in which the carrier comprises saline solution, glucose solution or a mixture of saline and glucose solution.
- injectable suspensions may also be prepared in which case appropriate liquid carriers, suspending agents and the like may be employed.
- the present combinations can be formulated in an oral tablet form further comprising pharmaceutically acceptable excipients having a weight ranging between 150 mg and 600 mg, suitable ranging between 200 and 400 mg.
- Convenient oral tablet forms containing the active ingredients according to the present invention have a total nominal weight ranging between 200 mg and 1500 mg, suitably between 500 mg and 1250 mg, more suitable between 600 and 1100 mg.
- an advantage of the pharmaceutical formulations of the invention resides in the fact that each of the ingredients of the present combinations can be co-formulated in one pharmaceutical formulation and do not have to be administered separately.
- the daily therapeutic antiretroviral amount of the ingredients of the present combinations of such co-formulated single pharmaceutical form preferably is administered in a single unit dosage form but, if desired, also multiple unit dosage forms, such as two, three, four, five or even more unit dosage forms may be administered.
- a physician will be able to determine the exact dosage to be given taking into account the severity of the patient's condition as well as the patient's weight, gender and possibly other parameters such as individual differences in absorption, biodistribution, metabolism and excretion rates for each drug as well as other factors known to those skilled in the art.
- This invention also provides a method of treating HIV infected patients said method comprising administering a combination as specified herein.
- a method of treating HIV infected patients comprising administering TMC278 or its stereoisomeric form or pharmaceutically acceptable salt or its prodrug, in combination with a nucleoside reverse transcriptase inhibitor and/or a nucleotide reverse transcriptase inhibitor, in which method a therapeutically effective amount of TMC278 and the nucleoside reverse transcriptase inhibitor and/or nucleotide reverse transcriptase inhibitor can be administered once daily.
- a method of treating HIV infected patients comprising administering TMC278 or its stereoisomeric form or pharmaceutically acceptable salt or its prodrug, in combination with a nucleoside reverse transcriptase inhibitor, in which method a therapeutically effective amount of TMC278 and the nucleoside reverse transcriptase inhibitor can be administered once daily.
- a further aspect of this invention concerns a method of treating HIV infected patients said method comprising administering TMC278 or its stereoisomeric form or pharmaceutically acceptable salt or its prodrug, and a nucleotide reverse transcriptase inhibitor, in which method a therapeutically effective amount of TMC278 and the nucleotide reverse transcriptase inhibitor can be administered once daily.
- Still a further aspect of this invention comprises a method of treating HIV infected patients said method comprising administering TMC278 or its stereoisomeric form or pharmaceutically acceptable salt or its prodrug, in combination with a nucleoside reverse transcriptase inhibitor, and a nucleotide reverse transcriptase inhibitor, in which method a therapeutically effective amount of TMC278, the nucleotide reverse transcriptase inhibitor and the nucleoside reverse transcriptase inhibitor can be administered once daily.
- Still a further aspect of this invention comprises a method of treating HIV infected patients said method comprising administering TMC278 or its stereoisomeric form or pharmaceutically acceptable salt or its prodrug, in combination with a nucleoside reverse transcriptase inhibitor, and a second nucleoside reverse transcriptase inhibitor different from the former nucleoside reverse transcriptase inhibitor, in which method a therapeutically effective amount of TMC278, the nucleoside reverse transcriptase inhibitors can be administered once daily.
- the active ingredients in the methods of the invention are administered in therapeutically effective amounts, the latter meaning an amount that is sufficient to exert a sufficient HIV inhibitory effect during a certain time period, i.e. the time period between each intake of the formulations, preferably for about 24 hours.
- Particular embodiments are methods as specified above wherein one or more of the specific active ingredients mentioned herein such as emtricitabine, racemic FTC, lamivudin, tenofovir and its prodrug tenofovir disoproxil fumarate, are administered.
- specific active ingredients mentioned herein such as emtricitabine, racemic FTC, lamivudin, tenofovir and its prodrug tenofovir disoproxil fumarate
- One embodiment of the present invention relates to the present combinations for use as a medicine. Another embodiment relates to the combinations of the present invention for use in the manufacture of a medicament to treat HIV infected patients.
- TMC278 is E-TMC287, or preferably TMC278 hydrochloride salt or more preferably E-TMC278 hydrochloride salt.
- the combinations of this invention are especially useful for the treatment of AIDS and related clinical conditions such as AIDS related complex (ARC), progressive generalised lymphadenopathy (PGL) or AIDS related neurological conditions such as multiple sclerosis.
- ARC AIDS related complex
- PDL progressive generalised lymphadenopathy
- AIDS related neurological conditions such as multiple sclerosis.
- the present triple combination may be particularly useful for the treatment of drug-na ⁇ ve HIV infected patients.
- the combinations of the invention are also useful for the prevention of HIV transmission or infection in humans, in particular sexual transmission.
- the present invention relates to the use of combinations according to the present invention for the manufacture of a medicament for the prevention of HIV infection or transmission via sexual intercourse or related intimate contact between partners.
- the invention also relates to a method of preventing HIV infection or transmission via sexual intercourse or related intimate contact between partners comprising administering to a subject in need thereof an effective amount of any of the combinations according to the present invention.
- the respective daily dose for each of the active ingredients of a combination according to the present invention may range between 10 mg and 800 mg, preferably between 50 and 400 mg, more preferably between 50 and 300 mg, or between 100 and 300 mg.
- the daily dose for TMC278 may range between 10 mg and 500 mg, preferably between 10 and 300, more preferably between 50 and 250 mg, still more preferably between 50 and 200 mg, e.g. about 100 mg.
- the weight ratio of each couple of components of the triple combination taken on a daily basis may vary in a range from 1/10 to 10/1.
- the weight ratio of each couple varies between 1/6 and 6/1, more suitably 1/4 and 4/1, preferably between 1/3 and 3/1, and more preferably between 1/2 and 2/1.
- Table 2 lists some examples of the daily dose for each of the active ingredients in combinations of compound E-TMC278, emtricitabine and tenofovir.
- Combination no. E-TMC278 Emtricitabine Tenofovir 1 50 mg 200 mg — 2 50 mg — 300 mg 3 100 mg 200 mg — 4 100 mg — 300 mg 5 200 mg 200 mg — 6 200 mg — 300 mg 7 50 mg 200 mg 300 mg 8 100 mg 200 mg 300 mg 9 200 mg 200 mg 300 mg
- Table 3 lists some examples of the daily dose for each of the active ingredients in combinations of TMC278, abacavir and lamivudine wherein the dose mentioned in the table for abacavir sulfate is the equivalent dose of abacavir base.
- an interesting combination according to the present invention comprises compound E-(A) in a daily dose ranging between 10 mg and 500 mg, a daily dose of 150 mg lamivudine and a daily dose of an equivalent of 300 mg abacavir base.
- a daily dose ranging between 10 mg and 500 mg
- a daily dose of 150 mg lamivudine a daily dose of 150 mg lamivudine
- a daily dose of an equivalent of 300 mg abacavir base is formulated in a single pharmaceutical form.
- Another interesting combination according to the present invention comprises compound E-(A) in a daily dose ranging between 50 mg and 250 mg, a daily dose of 150 mg lamivudine and a daily dose of an equivalent of 300 mg abacavir base.
- a daily dose ranging between 50 mg and 250 mg
- a daily dose of 150 mg lamivudine a daily dose of 150 mg lamivudine
- a daily dose of an equivalent of 300 mg abacavir base is formulated in a single pharmaceutical form.
- the present invention also relates to a pharmaceutical composition in a form adapted to be applied to a site where sexual intercourse or related intimate contact can take place, such as the genitals, rectum, mouth, hands, lower abdomen, upper thighs, especially the vagina and mouth, comprising a pharmaceutically acceptable carrier and as active ingredients an effective amount of a combination according to the present invention.
- a pharmaceutical composition in a form adapted to be applied to a site where sexual intercourse or related intimate contact can take place, such as the genitals, rectum, mouth, hands, lower abdomen, upper thighs, especially the vagina and mouth, comprising a pharmaceutically acceptable carrier and as active ingredients an effective amount of a combination according to the present invention.
- a pharmaceutically acceptable carrier as active ingredients an effective amount of a combination according to the present invention.
- compositions usually employed for being applied to the vagina, rectum, mouth and skin such as for example gels, jellies, creams, ointments, films, sponges, foams, intravaginal
- an effective amount of each of the particular compounds of the triple combination as the active ingredients is combined in intimate admixture with a pharmaceutically acceptable carrier, which carrier may take a wide variety of forms depending on the form of administration.
- a pharmaceutically acceptable carrier which carrier may take a wide variety of forms depending on the form of administration.
- a bioadhesive in particular a bioadhesive polymer.
- a bioadhesive may be defined as a material that adheres to a live biological surface such as for example a mucus membrane or skin tissue.
- the present invention also relates to a pharmaceutical composition
- a pharmaceutical composition comprising a pharmaceutically acceptable carrier and as active ingredients an effective amount of each of the compounds of the present triple combination characterized in that the pharmaceutical composition is bioadhesive to the site of application.
- the site of application is the vagina, rectum, mouth or skin, most preferred is the vagina.
- Immature monocyte derived dendritic cells represent a good model for interstitial dendritic cells, which are early targets during sexual HIV transmission and important initiators of the immune response.
- These immMO-DC were used in “in vitro” models to test the prevention of HIV infection via sexual intercourse or related intimate contact between partners.
- One such model is described in the experimental part and indicates that the TMC278 potently inhibits HIV replication in MO-DC/CD4(+) T cell co-cultures.
- Table 4 shows that high and dose-proportional exposures were obtained.
- the correlation coefficient for the 5 C max datapoints is 0.9897 and for the area under the curve values between 0 and 48 hours (AUC 0-48 hr ) 0.9952.
- Half-life of plasma concentrations ranged between 37 and 39 hours. The compound was well tolerated by the volunteers. No relevant adverse effects of the drug were noted.
- Compound E-TMC278 was tested in a cell-based assay, using natural host cells of HIV.
- MT-4 cells a cell line of human T cells
- HIV-1 wild type or mutants
- Cytotoxicity was determined in parallel with the antiviral activity so that the selectivity of the antiviral effect could be assessed.
- Active compounds have to penetrate the cell membrane in order to interfere with replication steps inside the cell.
- IC50 50% inhibitory concentration for inhibition of viral cytopathicity
- IC90 50% cytotoxic concentration
- CC50 50% cytotoxic concentration
- the ratio CC50/IC50 also called the selectivity index, is an indication of the specificity of the antiviral effect.
- Tested HIV strains included: Wild type (wt) HIV-1; a panel of single and double mutants, obtained by site-directed mutagenesis (SDM), and a panel of clinical isolates, selected for resistance against NNRTIs.
- a limited panel of HIV-1 mutants was constructed using site-directed mutagenesis (SDM) and homologous recombination techniques.
- Compound E-TMC278 was tested against an extended panel of single and double mutants known to be resistant against commercially available NNRTIs.
- Nevirapine (NVP) and efavirenz (EFV) were included as controls.
- NNRTIs are highly selective inhibitors of HIV-1 but their current clinical use is limited by the rapid emergence of NNRTI (cross-) resistance. The rate of resistance emergence against compound E-TMC278 and the first generation NNRTIs nevirapine and efavirenz was compared in vitro.
- MT4 cells were infected with wild type HIV-1 at high multiplicity of infection (>1 infectious virus per cell, to maximize the genetic diversity of the virus population) in the presence of various concentrations of compound E-TMC278 (40, 200, 1000 and 5000 ⁇ IC50), and were monitored twice a week for virus replication. Emerging virus was collected for pheno- and genotyping. Cultures without evidence of virus replication were further sub-cultivated in the presence of the same concentration of inhibitor for a total duration of 30 days (10 passages).
- HIV-1 resistant to first generation NNRTIs
- emergence of HIV-1, resistant to compound E-TMC278 was delayed or did not occur.
- Compound E-TMC278 had little or no effect on cardiovascular and pulmonary parameters in vivo at plasma levels covering and exceeding the targeted plasma levels in man and at concentrations in vitro covering or exceeding the anti-viral concentration in vitro.
- Example 3 In Vitro Models to Test the Ability of Compound E-TMC278 to Prevent HIV Infection Via Sexual Intercourse or Related Intimate Contact Between Partners
- monocyte-derived dendritic cells were infected for 2 hours with the monotropic HIV strain Ba-L at a multiplicity of infection (MOI) of 10-3. After infection, cells were washed 6 times and resuspended in 10% BCS at 400.000 cells/ml.
- Autologous CD4(+) T cells were purified out of the lymphocyte fraction of the same elutration as the MO-DC and used at a concentration of 2 ⁇ 10 6 cells/ml ((ratio MO-DC/CD4(+) T: 1/5).
- test compound A serial dilution of a compound of formula (I) (test compound) was added to the MO-DC/CD4(+) T cell co-cultures. Each experiment was done in 96-well plates, in which each cup contained 50 ⁇ l of MO-DC, 50 ⁇ l of CD4(+) T cells and 100 ⁇ l of test compound. Half of the culture medium, with test compound, was refreshed twice weekly.
- Emtricitabine 300 mg Tenofovir diisoproxyl fumarate 300 mg E-TMC278 hydrochloride salt 110 mg HPMC 2910 15 mPa ⁇ s 24 mg Polysorbate 20 6 mg Crosspolyvidone 18 mg Lactose monohydrate 43 mg Magnesium stearate 3 mg Talcum 6 mg
- the active ingredients and lactose are fluidised and sprayed with a solution of HPMC and polysorbate in water (at an equivalent of 120 ml/tablet). Subsequently crosspolyvidone is added, while still being fluidised, followed by magnesium stearate and talcum. The thus obtained granulate is compressed into 13 mm cylindrical tablets using standard compressing equipment.
Abstract
The present invention concerns combinations of a pyrimidine containing NNRTI with nucleoside reverse transcriptase inhibitors and nucleotide reverse transcriptase inhibitors useful for the treatment of HIV infected patients or for the prevention of HIV transmission or infection.
Description
- This application is a continuation of U.S. application Ser. No. 16/784,404, filed Feb. 7, 2020, which is a continuation of U.S. application Ser. No. 16/360,693, filed Mar. 21, 2019, now abandoned, which is a continuation of U.S. application Ser. No. 15/950,548, filed Apr. 11, 2018, now abandoned, which is a continuation of U.S. application Ser. No. 15/383,076, filed Dec. 19, 2016, now abandoned, which is a continuation of U.S. application Ser. No. 14/744,501, filed Jun. 19, 2015, now abandoned, which is a continuation of U.S. application Ser. No. 14/454,045, filed Aug. 7, 2014, now abandoned, which is a continuation of U.S. application Ser. No. 12/574,881, filed Oct. 7, 2009, now U.S. Pat. No. 8,841,310, which is a continuation of U.S. application Ser. No. 10/570,228, filed Feb. 28, 2006, now abandoned, which is the National Stage Entry of International Application No. PCT/EP2004/052028, filed Sep. 3, 2004, which claims the benefit of European Application Nos. 03103668.4 filed Oct. 2, 2003, 03103335.0, filed Sep. 10, 2003, 03103319.4, filed Sep. 8, 2003, and 03103275.8, filed Sep. 3, 2003 and U.S. Provisional Application Nos. 60/508,486, filed Oct. 3, 2003 and 60/499,771, filed Sep. 3, 2003.
- The present invention concerns combinations of a pyrimidine containing NNRTI with nucleoside reverse transcriptase inhibitors and/or nucleotide reverse transcriptase inhibitors useful for the treatment of HIV infected patients or for the prevention of HIV transmission or infection.
- Despite the fact that significant progress has been made by the introduction of HAART therapy (Highly Active Anti-Retroviral Therapy), resistance of the HIV virus against nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), nucleotide reverse transcriptase inhibitors (NtRTIs), protease inhibitors and even the more recent fusion inhibitors is still a major cause of therapy failure. For instance, half of the patients receiving anti-HIV combination therapy do not respond fully to the treatment, mainly because of resistance of the virus to one or more drugs used. Moreover, it has been shown that resistant virus is carried over to newly infected individuals, resulting in severely limited therapy options for these drug-naive patients. On the International AIDS Conference in Paris in July 2003, researchers released that the biggest study so far of resistance to AIDS drugs finds that about 10 percent of all newly infected people in Europe have drug-resistant strains. Smaller tests to determine the spread of resistance have been done in the high-risk city center of San Francisco. This test showed the highest level of resistance at 27 percent.
- The pharmacokinetic profile of many commercially available antiretrovirals does not allow relatively low therapeutic doses. Poor pharmacokinetic profiles often in combination with poor solubility properties of the antiretrovirals cause the AIDS patient to face a high pill burden which is particularly undesirable for drug-naïve patients or first line therapy. Moreover, as a consequence of the AIDS virus even resisting antiretroviral combination therapy, a physician will boost the plasma levels of the active drugs in order for said antiretrovirals to regain effectivity against the mutated HIV viruses, the consequence of which is an even higher increase in pill burden. Boosting plasma levels may also lead to an increased risk of non-compliance with the prescribed therapy and to increased side-effects.
- Several attempts have been made to date to design combination regimens. For instance, the combination of lamivudine (a nucleoside RT inhibitor also named 3TC) at a 150 mg dose and zidovudine (a nucleotide RT inhibitor also named AZT) at a 300 mg dose, formulated in an oral tablet and dosed twice daily, or the combination of abacavir sulfate at a dose equivalent to 300 mg abacavir (a nucleoside RT inhibitor), lamivudine at a 150 mg dose and zidovudine at a 300 mg dose, formulated in an oral tablet and dosed twice daily.
- WO 93/23021 describes therapeutic combinations for the treatment of HIV-infections comprising zidovudine and an agent serving to enhance the antiviral activity against HIV populations otherwise resistant to zidovudine.
- WO 96/01110 describes a triple combination of zidovudine, lamivudine and loviride, the latter being a non-nucleoside RT inhibitor of the α-APA class.
- An overview of new antiretroviral drugs is given in Clinical Microbiology and Infection 2003, Vol. 9: 3, pp. 186-193.
- WO 03/016306 specifically discloses more than 250 pyrimidine derivative having HIV replication inhibiting properties that act as non-nucleoside RT inhibitors (NNRTIs) having the ability to inhibit the replication both wild-type and of mutant strains. One of said NNRTIs is 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]-amino]-2-pyrimidinyl]amino]-benzonitrile (herein referred to as TMC278). WO 03/016306 also discloses the methods to synthesize these compounds. It further discloses combinations of said NNRTIs with other antiretrovirals, i.e. suramine, pentamidine, thymopentin, castanospermine, dextran (dextran sulfate), foscamet-sodium (trisodium phosphono formate), zidovudine (3′-azido-3′-deoxythymidine, AZT), didanosine (2′,3′-di-deoxyinosine; ddI), zalcitabine (dideoxycytidine, ddC), lamivudine (2′-3′-dideoxy-3′-thiacytidine, 3TC), stavudine (2′,3′-didehydro-3′-deoxythymidine, d4T), abacavir, nevirapine (11-cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido-[3,2-b:2′,3′-e][1,4]diazepin-6-one), efavirenz, delavirdine, TMC120, TMC125, tenofovir, (S)-8-chloro-4,5,6,7-tetrahydro-5-methyl-6-(3-methyl-2-butenyl)imidazo-[4,5,1-jk][1,4]benzodiazepine-2(1H)-thione, α-[(2-nitrophenyl)amino]-2,6-dichloro-benzene-acetamide, RO-5-3335, indinavir, ritonavir, saquinavir, lopinavir (ABT-378), nelfinavir, amprenavir, TMC126, BMS-232632, VX-175, T-20, T-1249, AMD-3100 and hydroxyurea.
- Notwithstanding existing combination therapy, there is still a need for improved antiretroviral therapy, more particularly AIDS therapy. This need is particularly acute for therapy that is effective not only on wild type HIV virus, but also on the increasingly more common resistant HIV viruses. It is thus highly desirable especially for first line therapy to design a combination regimen with a low pill burden that limits or even suppresses the recurrence of drug resistant virus and which can be used and remains effective for a long term.
- It is an object of the invention to provide combinations of more than one therapeutically effective antiretroviral drug, which combinations can be used as first line therapy in drug-naïve patients for a long period of time.
- It is also an object of the invention to provide combinations of more than one therapeutically effective antiretroviral drug in which the antiretroviral drugs have a complementary resistance profile thus creating a high resistance barrier and thus allowing a drug-naïve patient to take the combinations for a long period of time.
- Another object of the invention is to provide combinations of more than one therapeutically active antiretroviral drug wherein each of the active antiretroviral drugs of the combinations can be administered once daily thus reducing the pill burden for the patient.
- A further object of the invention is to provide combinations of more than one therapeutically active antiretroviral drug wherein each of the active antiretroviral drugs of the combinations can be co-formulated.
- Yet a further object of the invention is to provide combinations of more that one therapeutically active antiretroviral drug wherein a therapeutically effective amount of each of the active antiretroviral drugs of the combinations can be co-formulated in one single pharmaceutical formulation.
- Another object of the present invention is to provide combinations of more than one active antiretroviral drug which combinations can be used to prevent HIV transmission or infection in humans.
- All references cited herein are incorporated by reference.
- Thus in a first aspect, the present invention provides a combination comprising (i) TMC278 or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof; or a prodrug thereof; and (ii) a nucleoside reverse transcriptase inhibitor and/or a nucleotide reverse transcriptase inhibitor; wherein TMC278 and the nucleotide reverse transcriptase inhibitor and/or the nucleoside reverse transcriptase inhibitor are therapeutically effective HIV inhibitors at a dose that can be administered once daily.
- Thus in a second aspect, the present invention provides a combination comprising (i) TMC278 or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof; or a prodrug thereof; and (ii) a nucleoside reverse transcriptase inhibitor; wherein TMC278 and the nucleoside reverse transcriptase inhibitor are therapeutically effective HIV inhibitors at a dose that can be administered once daily.
- In a third aspect there is provided a combination comprising (i) TMC278 or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof; or a prodrug thereof; and (ii) a nucleotide reverse transcriptase inhibitor; wherein TMC278 and the nucleotide reverse transcriptase inhibitor are therapeutically effective HIV inhibitors at a dose that can be administered once daily.
- In a fourth aspect there is provided a triple combination comprising (i) TMC278 or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof; or a prodrug thereof; and (ii) a nucleoside reverse transcriptase inhibitor; and (iii) a nucleotide reverse transcriptase inhibitor; wherein TMC278 and the nucleotide reverse transcriptase inhibitor and the nucleoside reverse transcriptase inhibitor are therapeutically effective HIV inhibitors at a dose that can be administered once daily.
- In a fifth aspect there is provided a triple combination comprising (i) TMC278 or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof; or a prodrug thereof; and (ii) a nucleoside reverse transcriptase inhibitor; and (iii) a second nucleoside reverse transcriptase inhibitor different from the nucleoside reverse transcriptase inhibitor of (ii); wherein TMC278 and the first and second nucleoside reverse transcriptase inhibitors are therapeutically effective HIV inhibitors at a dose that can be administered once daily.
- In another aspect there is provided a pharmaceutical formulation comprising a pharmaceutically acceptable carrier and a combination as specified herein.
- The invention also concerns the use of the combinations specified herein as HIV inhibitors and the use thereof in the treatment of HIV infected patients or in the prevention of HIV transmission or infection.
- The invention is based on the finding that TMC278 is a potent reverse transcriptase inhibitor that has an extremely high genetic barrier in combination with a favourable pharmacokinetic profile allowing once daily dosing. It was surprising to discover that TMC278 has all these properties together. This is unusual because one cannot predict what mutations will be selected in the HIV-1 genome by a given drug, whether the mutated virus will have any chance of survival under the pressure of the drug, how much drug is needed to limit or to suppress the recurrence of such mutated virus, and at what frequency such drug has to be given to maintain suppression of the development of a resistant virus that can break through the genetic barrier of the drug.
- As used herein the term ‘therapeutically effective HIV inhibitors at a dose that can be administered once daily’ means that the HIV inhibitors are suitable for dosing every 24 hours. The ‘term suitable for dosing every 24 hours’ means that the HIV inhibitors are such that they can be administered every 24 hours and give effective blood plasma concentrations of the active ingredients such that they are effective to suppress HIV infection over a period of 24 hours. The HIV inhibitors for use in the invention can be dosed every 24 hours.
- TMC278 or 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]-amino]-2-pyrimidinyl]-amino]-benzonitrile is a known NNRTI, which can be prepared as described in WO03/016306. TMC278 can be used in base form or, which is preferred, as a suitable pharmaceutically acceptable salt form, in particular as an acid addition salt form. The pharmaceutically acceptable addition salts are meant to comprise the therapeutically active non-toxic salt forms. The acid addition salt forms can be obtained by treating the base form with appropriate acids as inorganic acids, for example, hydrohalic acids, e.g. hydrochloric, hydrobromic and the like; sulfuric acid; nitric acid; phosphoric acid and the like; or organic acids, for example, acetic, propanoic, hydroxyacetic, 2-hydroxy-propanoic, 2-oxopropanoic, oxalic, malonic, succinic, maleic, fumaric, malic, tartaric, 2-hydroxy-1,2,3-propanetricarboxylic, methanesulfonic, ethanesulfonic, benzene-sulfonic, 4-methylbenzenesulfonic, cyclohexanesulfamic, 2-hydroxybenzoic, 4-amino-2-hydroxybenzoic and the like acids. Preferred for use in the present invention are the hydrohalic acid salts, in particular the hydrochloride salt.
- TMC278 occurs in stereoisomeric forms, more in particular as E- and Z-isomeric forms. Both isomers may be used in the combinations of the present invention. Whenever reference is made herein to TMC278, the E- and the Z-form as well as any mixture of both forms are meant to be included.
- A preferred form of TMC278 for use in the invention is the E-isomer, i.e. (E)-4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]-amino]-2-pyrimidinyl]-amino]-benzonitrile (hereinafter called E-TMC278). The Z-isomer of TMC278, i.e. (Z)-4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]-amino]-2-pyrimidinyl]-amino]-benzonitrile (hereinafter called compound Z-TMC278) can also be used. It has relatively high potency against wild-type HIV-1 but is less active against single and double mutants in comparison to the E-isomer. Table 1 shows the IC50 value in nM of the E and Z-isomer of TMC278.
-
TABLE 1 HIV RT mutation E-isomer Z-isomer Wild-type 0.4 0.6 100I 0.4 6.3 103N 0.3 1.6 181C 1.3 5.0 188L 2.0 32 227C 2.0 4.0 100I + 103N 7.9 790 103N + 181C 1.0 40 227L + 106A 1.0 4.0 - Whenever reference is made herein to the E-form of TMC278 (i.e. E-TMC278), the pure E-isomer or any isomeric mixture of the E- and the Z-forms wherein the E-form is predominantly present is meant to be comprised, i.e. an isomeric mixture containing more than 50% or in particular more than 80% of the E-form, or even more than 90% of the E-form. Of particular interest is the E-form substantially free of the Z-form. Substantially free in this context refers to E-Z-mixtures with no or almost no Z-form, e.g. isomeric mixtures containing as much as 90%, in particular 95% or even 98% or 99% of the E-form. Equally, whenever reference is made herein to the Z-form of TMC278 (i.e. Z-TMC278), the pure Z-isomer or any isomeric mixture of the Z- and the E-forms wherein the Z-form is predominantly present is meant to be comprised, i.e. an isomeric mixture containing more than 50% or in particular more than 80% of the Z-form, or even more than 90% of the Z-form. Of particular interest is the Z-form substantially free of the E-form. Substantially free in this context refers to E-Z-mixtures with no or almost no E-form, e.g. isomeric mixtures containing as much as 90%, in particular 95% or even 98% or 99% of the Z-form.
- Also meant to be included for use in this invention are salts of the isomeric forms of TMC278, in particular the salts mentioned above. Of particular interest are Z-TMC278 hydrochloride and specifically E-TMC278 hydrochloride.
- Advantageously, the nucleotide reverse transcriptase inhibitor and the nucleoside reverse transcriptase inhibitor select mutations in the reverse transcriptase that do not cause resistance to TMC278. Of particular interest therefore is any combination specified herein wherein (1) TMC278 and the nucleoside/nucleotide reverse transcriptase inhibitor or inhibitors are therapeutically effective HIV inhibitors at a dose that can be administered once daily and (2) the nucleoside/nucleotide reverse transcriptase inhibitor or inhibitors select mutations in the reverse transcriptase that do not cause resistance to TMC278.
- Specifically, in one embodiment, a combination is provided comprising (i) TMC278 or its stereoisomeric form or pharmaceutically acceptable salt or its prodrug, and (ii) a nucleoside reverse transcriptase inhibitor, wherein (1) TMC278 and the nucleoside reverse transcriptase inhibitor are therapeutically effective HIV inhibitors at a dose that can be administered once daily and (2) the nucleoside reverse transcriptase inhibitor selects mutations in the reverse transcriptase that do not cause resistance to TMC278. In another embodiment, a combination is provided comprising (i) TMC278 or its stereoisomeric form or pharmaceutically acceptable salt or its prodrug, and (ii) a nucleotide reverse transcriptase inhibitor, wherein (1) TMC278 and the nucleotide reverse transcriptase inhibitor are therapeutically effective HIV inhibitors at a dose that can be administered once daily and (2) the nucleotide reverse transcriptase inhibitor selects mutations in the reverse transcriptase that do not cause resistance to TMC278.
- In a preferred embodiment, a triple combination is provided comprising (i) TMC278 or its stereoisomeric form or pharmaceutically acceptable salt or its prodrug, and (ii) a nucleoside reverse transcriptase inhibitor, and (iii) a nucleotide reverse transcriptase inhibitor, wherein (1) TMC278 and the nucleotide reverse transcriptase inhibitor and the nucleoside reverse transcriptase inhibitor are therapeutically effective HIV inhibitors at a dose that can be administered once daily and (2) the nucleotide reverse transcriptase inhibitor and the nucleoside reverse transcriptase inhibitor select mutations in the reverse transcriptase that do not cause resistance to TMC278.
- In another preferred embodiment, a triple combination is provided comprising (i) TMC278 or its stereoisomeric form or pharmaceutically acceptable salt or its prodrug, and (ii) a nucleoside reverse transcriptase inhibitor, and (iii) a second nucleoside reverse transcriptase inhibitor different from the nucleoside reverse transcriptase inhibitor of (ii); wherein (1) TMC278 and the nucleoside reverse transcriptase inhibitors are therapeutically effective HIV inhibitors at a dose that can be administered once daily and (2) the nucleoside reverse transcriptase inhibitors select mutations in the reverse transcriptase that do not cause resistance to TMC278.
- Preferred nucleotide reverse transcriptase inhibitors that can be used in the combinations subject of this invention include tenofovir and its prodrug tenofovir disoproxil fumarate.
- Tenofovir is an adenosine nucleotide analogue currently commercially available with activity against retroviruses. Tenofovir disoproxil fumarate (tenofovir DF) is a once-daily, orally administered prodrug of tenofovir. For antiviral activity, tenofovir DF needs to be hydrolysed to the ANP analogue and then phosphorylated to the active diphosphate moiety [Arimilli et al Antiviral Chemistry and Chemotherapy 1997, 8:6 (557-564); Fridland et al. Antiviral Research 1997, 34]. After entry in to lymphocytes or macrophages, the prodrug is quantitatively converted to the parent analogue, tenofovir, and phosphorylated to mono- and diphosphate metabolites. The cellular enzymes that are responsible for phosphorylation of this drug are adenylate kinase and nucleoside diphosphate kinase [Robbins et al. Antimicrobial Agents and Chemotherapy 1995, 39:10 (2304-2308); Robbins et al. Antimicrobial Agents and Chemotherapy 1998, 42:3 (612-617)]. Unlike other nucleoside analogues, such as zidovudine or stavudine, both of whose phosphorylation is cell cycle-dependent, tenofovir is efficiently phosphorylated in resting as well as cycling peripheral blood lymphocytes [Robbins et al. 1998]. Tenofovir can inhibit HIV-1 replication in different cell types that may target HIV, including primary human blood lymphocytes and macrophages [Perno et al. Antiviral Research 1992 (289-304); Perno et al. Molecular Pharmacology 1996, 50:2 (359-366)]. The primary target of tenofovir diphosphate is reverse transcriptase (RT). Tenofovir diphosphate is a competitive inhibitor for the incorporation of deoxyadenosine triphosphate into nascent proviral DNA chains. Inhibition of HIV-1 RT by tenofovir diphosphate has an inhibition constant of approximately 0.9 μM, and if the analogue is incorporated into the growing viral DNA chain it may terminate further chain elongation. Tenofovir inhibits viral RT much more effectively than it inhibits cellular DNA polymerases [Suo et al Journal of Biological Chemistry 1998, 273:42 (2750-2758)]. The concentration required to inhibit the replication of various HIV-1 strains by 50% (EC50) in lymphocyte and macrophage cell types (MT-2, CEM, ACH8) ranges from 0.2 to 10 μM. The antiviral effect is achieved at non-toxic doses of tenofovir (selectivity index ranging from 100 to 2000). Tenofovir D F is currently available as 300 mg tablets to be taken once daily.
- Viral resistance to tenofovir in vitro emerges slowly. A recombinant virus expressing the K65R mutation showed a 3-fold decreased susceptibility to tenofovir in vitro [Cherrington et al. Interscience Conference on Antimicrobial Agents and Chemotherapy 1997, 37th]. Notably, clinical HIV strains expressing the M184V lamivudine-associated resistance mutation on RT show wild-type or increased susceptibility to tenofovir in vitro, independent of changes in Ki for the mutant enzyme [Miller et al. Interscience Conference on Antimicrobial Agents and Chemotherapy 1998,]. Long-term treatment (5 to 15 weeks) of newborn rhesus macaques with tenofovir (doses of 30 mg/kg) starting 3 weeks after inoculation with simian immunodeficiency virus, resulted in emergence of SIV with approximately 5-fold decreased susceptibility to tenofovir [Van Rompay et al. Antimicrobial Agents and Chemotherapy 1996, 40:11 (2586-2591)]. This low level of resistance was associated with the appearance of the K65R mutation.
- In a preferred embodiment, a combination is provided comprising (i) TMC278 or its stereoisomeric form or pharmaceutically acceptable salt or its prodrug, and (ii) tenofovir or its prodrug tenofovir disoproxil fumarate, wherein TMC278 and tenofovir or its prodrug tenofovir disoproxil fumarate are therapeutically effective HIV inhibitors at a dose that can be administered once daily.
- In another preferred embodiment, a triple combination is provided comprising (i) TMC278 or its stereoisomeric form or pharmaceutically acceptable salt or its prodrug, and (ii) a nucleoside reverse transcriptase inhibitor, and (iii) tenofovir disoproxil fumarate; wherein TMC278 and the nucleoside reverse transcriptase inhibitor and tenofovir disoproxil fumarate are therapeutically effective HIV inhibitors at a dose that can be administered once daily.
- Preferred nucleoside reverse transcriptase inhibitors that can be used in the combinations of this invention include abacavir or a pharmaceutically acceptable salt thereof, emtricitabine, racemic FTC and lamivudine (also named 3TC).
- Emtricitabine or (−)-FTC is the left (−) rotatory enantiomeric form of racemic FTC or (+)-cis-4-amino-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-2(1H)-pyrimidinone (FTC). It is a commercially available nucleoside analogue and exhibits activity against HIV-1 [Hoong et al. Journal of Organic Chemistry 1992 (5563-5565); Jeong et al Journal of Medicinal Chemistry 1993, 36:2 (181-195); Van Roey et al. Antiviral Chemistry and Chemotherapy 1993, 4:6 (369-375]. The in vitro anti-HIV-1 activity of (−)-beta-enantiomer of FTC was reported to be 20-fold more than the (+)-beta-enantiomer, and the (+)-enantiomer was significantly more toxic than the (−)-enantiomer to myeloid progenitor cells [Schinazi et al Antimicrobial Agents and Chemotherapy 1992, 36:11 (2423-2431)]. The potential for HIV-1 resistance to FTC was evaluated by serial passage of the virus in human PBMCs and MT-2 cells in the presence of increasing drug concentrations. Highly drug-resistant HIV-1 variants dominated the replicating virus population after two or more cycles of infection. RT derived from drug-resistant viral particles was 15- to 50-fold less susceptible to the 5′-triphosphate of FTC compared with the enzyme from parental drug susceptible virus. DNA sequence analysis of the RT gene amplified from resistant viruses consistently identified mutations at codon 184 from Met (ATG) to Val (GTG or GTA) [Schinazi et al Antimicrobial Agents and Chemotherapy 1993, 37:4 (875-881); Tisdale et al Antiviral Research 1993, 20:Suppl 1; Smith et al Journal of Virology 1997, 71:3 (2357-2362); Harrer et al Journal of Infectious Diseases 1996, 173:2 (476-479); Tisdale et al Proceedings of the National Academy of Sciences of the United States of America 1993, 90:12 (5653-5656)]. Due to this observed single mutation in the YMDD of reverse transcriptase in the HIV-infected patients, (−)-FTC is not suitable for monotherapy and needs to be administered in combination with other antiretroviral agents to effectively treat patients infected with HIV. Emtricitabine is available as 200 mg capsules to be taken once a day.
- Lamivudine has the chemical name (−)-2′,3′-dideoxy-3′-thiacytidine and is described for instance in EP-382 526 as an antiviral nucleoside analogue. It is also a well established and useful antiretroviral which is commercially available for instance as 150 mg oral tablets. Lamivudine is also commercially available in combination with zidovudine (300 mg zidovudine/150 mg lamivudine), and in combination with lamivudine and abacavir sulfate (300 mg zidovudine/150 mg lamivudine/equivalent of 300 mg abacavir).
- Abacavir is a well established and useful antiretroviral which is commercially available for instance as an oral solution of abacavir sulfate in a strength equivalent to 20 mg abacavir base/ml, or as an oral tablet of abacavir sulfate in a strength equivalent to 300 mg abacavir base. Abacavir sulfate is also commercially available in combination with lamivudine and zidovudine (300 mg zidovudine/150 mg lamivudine/equivalent of 300 mg abacavir).
- Abacavir is a carbocyclic nucleoside with potent and selective anti-HIV activity. Abacavir in its optically active form is disclosed in EP-434 450. The cis-isomer of abacavir with unspecified absolute stereochemical configuration is described in EP-349 242. Abacavir is one of the most potent NRTI developed to date. An average reduction in viral load of more than 1.4 log 10 RNA copies/ml is observed after a short course of abacavir monotherapy. In vitro, resistant virus is not rapidly selected by abacavir. A significant decrease in susceptibility to abacavir in wild-type or zidovudine-resistant HIV-1 strains was not observed until after eight to ten passages in MT-4 cells. A set of resistance mutations at HIV reverse transcriptase (RT) codons, 65R, 74V, 115F and/or 184V, are selected during in vitro passage with abacavir, and a combination of these mutations was required to confer a 10-fold reduction in abacavir susceptibility in a laboratory strain of HIV. The first mutation detected upon passage of HIV-1 in an increasing concentration of abacavir is M184V, which confers only a 3-fold decrease in HIV-1 susceptibility. Phenotype resistance to 3TC and/or the presence of the 184V mutation does not prevent viral load response to abacavir therapy. Resistance to multiple nucleosides is associated with a decreased or absent response to abacavir [Kumar et al Antimicrobial Agents and Chemotherapy 1999, 43:3 (603-608); Lanier et al International Conference on Retroviruses and Opportunistic Infections 1998, 5th:Chicago; posted on 16 Apr. 1999].
- In a preferred embodiment, a combination is provided comprising (i) TMC278 or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof, or a prodrug thereof, and (ii) emtricitabine, wherein TMC278 and emtricitabine are therapeutically effective HIV inhibitors at a dose that can be administered once daily.
- In a preferred embodiment, a combination is provided comprising (i) TMC278 or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof, or a prodrug thereof, and (ii) lamivudine, wherein TMC278 and lamivudine are therapeutically effective HIV inhibitors at a dose that can be administered once daily.
- In another preferred embodiment, a combination is provided comprising (i) TMC278 or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof, or a prodrug thereof, and (ii) abacavir or a pharmaceutically acceptable salt thereof, characterized in that, TMC278 and abacavir are therapeutically effective HIV inhibitors at a dose that can be administered once daily.
- In another preferred embodiment, a combination is provided comprising (i) TMC278 or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof, or a prodrug thereof, and (ii) abacavir sulfate, characterized in that, TMC278 and abacavir sulfate are therapeutically effective HIV inhibitors at a dose that can be administered once daily.
- In another preferred embodiment, a triple combination is provided comprising (i) TMC278 or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof, or a prodrug thereof; and (ii) emtricitabine, and (iii) a nucleotide reverse transcriptase inhibitor, wherein TMC278 and the nucleotide reverse transcriptase inhibitor and emtricitabine are therapeutically effective HIV inhibitors at a dose that can be administered once daily.
- In another preferred embodiment, a triple combination is provided comprising (i) TMC278 or or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof, or a prodrug thereof; and (ii) lamivudine, and (iii) a nucleotide reverse transcriptase inhibitor, wherein TMC278 and the nucleotide reverse transcriptase inhibitor and lamivudine are therapeutically effective HIV inhibitors at a dose that can be administered once daily.
- In another preferred embodiment, a triple combination is provided comprising (i) TMC278 or or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof, or a prodrug thereof, and (ii) abacavir or a pharmaceutically acceptable salt thereof, or preferably abacavir sulfate, and (iii) a nucleotide reverse transcriptase inhibitor, wherein TMC278 and the nucleotide reverse transcriptase inhibitor and abacavir or a pharmaceutically acceptable salt thereof, or preferably abacavir sulphate, are therapeutically effective HIV inhibitors at a dose that can be administered once daily.
- In another preferred embodiment, a triple combination is provided comprising (i) TMC278 or or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof, or a prodrug thereof; and (ii) emtricitabine, and (iii) tenofovir or its prodrug tenofovir disoproxil fumarate, wherein TMC278 and emtricitabine and tenofovir or its prodrug tenofovir disoproxil fumarate are therapeutically effective HIV inhibitors at a dose that can be administered once daily.
- In another preferred embodiment, a triple combination is provided comprising (i) TMC278 or a stereoisomeric form thereof, or a pharmaceutically acceptable salt thereof, or a prodrug thereof, and (ii) lamivudine and (iii) tenofovir or its prodrug tenofovir disoproxil fumarate, wherein TMC278 and lamivudine and tenofovir or its prodrug tenofovir disoproxil fumarate are therapeutically effective HIV inhibitors at a dose that can be administered once daily.
- In another preferred embodiment, a triple combination is provided comprising (i) TMC278 or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof; or a prodrug thereof; and (ii) abacavir or a pharmaceutically acceptable salt form thereof, preferably abacavir sulfate; and (iii) tenofovir or its prodrug tenofovir disoproxil fumarate, wherein TMC278 and abacavir or a pharmaceutically acceptable salt form thereof, preferably abacavir sulfate and tenofovir or its prodrug tenofovir disoproxil fumarate are therapeutically effective HIV inhibitors at a dose that can be administered once daily.
- The following preferred triple combinations are also included
- (a) TMC278 or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof; or a prodrug thereof; with emtricitabine and tenofovir disoproxil fumarate;
- (b) TMC278 or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof; or a prodrug thereof; with lamivudine and tenofovir disoproxil fumarate.
- (c) TMC278 or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof; or a prodrug thereof; with abacavir sulfate and tenofovir disoproxil fumarate.
- (d) TMC278 or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof; or a prodrug thereof; with emtricitabine and lamivudine;
- (e) TMC278 or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof; or a prodrug thereof; emtricitabine and abacavir or a pharmaceutically acceptable salt thereof, preferably abacavir sulfate.
- (f) TMC278 or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof; or a prodrug thereof; abacavir or a pharmaceutically acceptable salt thereof, preferably abacavir sulfate and lamivudine.
- In particular, in each of the combinations (a)-(f) the active ingredients, in particular TMC278, emtricitabine, lamivudine, abacavir or a pharmaceutically acceptable salt form thereof, preferably abacavir sulfate, and tenofovir or its prodrug tenofovir disoproxil fumarate, are therapeutically effective HIV inhibitors at a dose that can be administered once daily.
- The double combinations of the present invention may contain one or more additional active ingredients, which can be agents useful for treating HIV infected patients or other active agents. The triple combinations of the present invention may equally contain one or more additional active ingredients, which can be agents useful for treating HIV infected patients or other active agents. Preferably any of these additional agents are therapeutically effective at a dose that can be administered once daily.
- The active ingredients of the combinations of the present invention may be administered simultaneously, concurrently or sequentially. Simultaneous administration may be done by employing a unitary pharmaceutical formulation or separate pharmaceutical formulations. In general, the combinations may be administered by topical, oral, rectal, intravenous, subcutaneous or intramuscular routes. For first line therapy of HIV infection, simultaneous administration employing a unitary pharmaceutical formulation is preferred.
- Thus, in another aspect there is provided a product containing a combination as specified herein as a combined preparation for simultaneous, separate or sequential use against HIV infection.
- The invention also provides a product containing (i) TMC278 or a stereoisomeric form thereof, or a pharmaceutically acceptable salt thereof, or a prodrug thereof, and (ii) a nucleoside reverse transcriptase inhibitor and/or a nucleotide reverse transcriptase inhibitor; wherein TMC278 and the nucleotide reverse transcriptase inhibitor and/or the nucleoside reverse transcriptase inhibitor are therapeutically effective HIV inhibitors at a dose that can be administered once daily; as a combined preparation for simultaneous, separate or sequential use against HIV infection.
- In a further aspect there is provided a product containing (i) TMC278 or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof, or a prodrug thereof, and (ii) a nucleoside reverse transcriptase inhibitor; wherein TMC278 and the nucleoside reverse transcriptase inhibitor are therapeutically effective HIV inhibitors at a dose that can be administered once daily; as a combined preparation for simultaneous, separate or sequential use against HIV infection.
- In another aspect there is provided a product containing (i) TMC278 or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof, or a prodrug thereof, and (ii) a nucleotide reverse transcriptase inhibitor, wherein TMC278 and the nucleotide reverse transcriptase inhibitor are therapeutically effective HIV inhibitors at a dose that can be administered once daily; as a combined preparation for simultaneous, separate or sequential use against HIV infection.
- In another aspect there is provided a product containing (i) TMC278 or a stereoisomeric form thereof, or a pharmaceutically acceptable salt thereof, or a prodrug thereof; and (ii) a nucleoside reverse transcriptase inhibitor; and (iii) a nucleotide reverse transcriptase inhibitor; wherein TMC278 and the nucleotide reverse transcriptase inhibitor and the nucleoside reverse transcriptase inhibitor are therapeutically effective HIV inhibitors at a dose that can be administered once daily; as a combined preparation for simultaneous, separate or sequential use against HIV infection.
- In another aspect there is provided a product containing (i) TMC278 or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof, or a prodrug thereof; and (ii) a nucleoside reverse transcriptase inhibitor; and (iii) a second nucleoside reverse transcriptase inhibitor other than the nucleoside reverse transcriptase inhibitor of (ii); wherein TMC278 and the nucleoside reverse transcriptase inhibitors are therapeutically effective HIV inhibitors at a dose that can be administered once daily; as a combined preparation for simultaneous, separate or sequential use against HIV infection.
- The active ingredients in the products of the invention are present in therapeutically effective amounts, the latter meaning an amount that is sufficient to exert a sufficient HIV inhibitory effect during a certain time period, i.e. the time period between each intake of the formulations, preferably for about 24 hours.
- Particular embodiments are products as specified above containing one or more of the specific active ingredients mentioned herein such as emtricitabine, racemic FTC, lamivudin, tenofovir and its prodrug tenofovir disoproxil fumarate.
- The products as mentioned above may contain separate formulations of the active ingredients, or two or where applicable more of the active ingredients may be co-formulated.
- In still a further aspect the invention provides pharmaceutical formulations containing a combination as specified herein and a suitable carrier.
- In another aspect there is provided a pharmaceutical formulation comprising a pharmaceutically acceptable carrier and as active ingredients (i) TMC278 or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof, or a prodrug thereof; and (ii) a nucleoside reverse transcriptase inhibitor and/or a nucleotide reverse transcriptase inhibitor; wherein TMC278 and the nucleoside reverse transcriptase inhibitor and/or the nucleotide reverse transcriptase inhibitor are therapeutically effective HIV inhibitors at a dose that can be administered once daily.
- The invention further provides a pharmaceutical formulation comprising a pharmaceutically acceptable carrier and as active ingredients (i) TMC278 or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof, or a prodrug thereof, and (ii) a nucleoside reverse transcriptase inhibitor; wherein TMC278 and the nucleoside reverse transcriptase inhibitor are therapeutically effective HIV inhibitors at a dose that can be administered once daily.
- In still another aspect there is provided a pharmaceutical formulation comprising a pharmaceutically acceptable carrier and as active ingredients (i) TMC278 or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof, or a prodrug thereof, and (ii) a nucleotide reverse transcriptase inhibitor, wherein TMC278 and the nucleoside reverse transcriptase inhibitor and the nucleotide reverse transcriptase inhibitor are therapeutically effective HIV inhibitors at a dose that can be administered once daily.
- In still another aspect there is provided a pharmaceutical formulation comprising a pharmaceutically acceptable carrier and as active ingredients (i) TMC278 or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof, or a prodrug thereof; and (ii) a nucleoside reverse transcriptase inhibitor; and (iii) a nucleotide reverse transcriptase inhibitor; wherein TMC278 and the nucleoside reverse transcriptase inhibitor and the nucleotide reverse transcriptase inhibitors are therapeutically effective HIV inhibitors at a dose that can be administered once daily.
- In still another aspect there is provided a pharmaceutical formulation comprising a pharmaceutically acceptable carrier and as active ingredients (i) TMC278 or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof, or a prodrug thereof; and (ii) a nucleoside reverse transcriptase inhibitor; and (iii) a second nucleoside reverse transcriptase inhibitor different from the nucleoside reverse transcriptase inhibitor of (ii); wherein TMC278 and the nucleoside reverse transcriptase inhibitors are therapeutically effective HIV inhibitors at a dose that can be administered once daily.
- The active ingredients in the pharmaceutical formulations of the invention are present in therapeutically effective amounts, the latter meaning an amount that is sufficient to exert a sufficient HIV inhibitory effect during a certain time period, i.e. the time period between each intake of the formulations, preferably for about 24 hours.
- Particular embodiments are pharmaceutical formulations as specified above containing one or more of the specific active ingredients mentioned herein such as emtricitabine, racemic FTC, lamivudin, tenofovir and its prodrug tenofovir disoproxil fumarate.
- The pharmaceutical formulations of the present invention may be formulated into various forms for different types of administration. To prepare the pharmaceutical formulations of this invention, effective amounts of the active ingredients, optionally in addition salt form, is combined in intimate admixture with a pharmaceutically acceptable carrier, which carrier may take a wide variety of forms depending on the form of preparation desired for administration. The pharmaceutical formulations of the invention are preferably formulated in unitary dosage form suitable, particularly, for administration orally, rectally, percutaneously, or by parenteral injection. For example, in preparing the formulations in oral dosage form, any of the usual pharmaceutical media may be employed such as, for example, water, glycols, oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs, emulsions and solutions; or solid carriers such as starches, sugars, kaolin, diluents, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules, and tablets. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit forms, in which case solid pharmaceutical carriers are obviously employed. For parenteral compositions, the carrier will usually comprise sterile water, at least in large part, though other ingredients, for example, to aid solubility, may be included. Injectable solutions, for example, may be prepared in which the carrier comprises saline solution, glucose solution or a mixture of saline and glucose solution. Injectable suspensions may also be prepared in which case appropriate liquid carriers, suspending agents and the like may be employed.
- In one aspect of the invention, the present combinations can be formulated in an oral tablet form further comprising pharmaceutically acceptable excipients having a weight ranging between 150 mg and 600 mg, suitable ranging between 200 and 400 mg. Convenient oral tablet forms containing the active ingredients according to the present invention have a total nominal weight ranging between 200 mg and 1500 mg, suitably between 500 mg and 1250 mg, more suitable between 600 and 1100 mg.
- An advantage of the pharmaceutical formulations of the invention resides in the fact that each of the ingredients of the present combinations can be co-formulated in one pharmaceutical formulation and do not have to be administered separately. The daily therapeutic antiretroviral amount of the ingredients of the present combinations of such co-formulated single pharmaceutical form preferably is administered in a single unit dosage form but, if desired, also multiple unit dosage forms, such as two, three, four, five or even more unit dosage forms may be administered. A physician will be able to determine the exact dosage to be given taking into account the severity of the patient's condition as well as the patient's weight, gender and possibly other parameters such as individual differences in absorption, biodistribution, metabolism and excretion rates for each drug as well as other factors known to those skilled in the art.
- This invention also provides a method of treating HIV infected patients said method comprising administering a combination as specified herein.
- Furthermore there is provided a method of treating HIV infected patients, said method comprising administering TMC278 or its stereoisomeric form or pharmaceutically acceptable salt or its prodrug, in combination with a nucleoside reverse transcriptase inhibitor and/or a nucleotide reverse transcriptase inhibitor, in which method a therapeutically effective amount of TMC278 and the nucleoside reverse transcriptase inhibitor and/or nucleotide reverse transcriptase inhibitor can be administered once daily.
- Furthermore there is provided a method of treating HIV infected patients, said method comprising administering TMC278 or its stereoisomeric form or pharmaceutically acceptable salt or its prodrug, in combination with a nucleoside reverse transcriptase inhibitor, in which method a therapeutically effective amount of TMC278 and the nucleoside reverse transcriptase inhibitor can be administered once daily.
- In a further aspect of this invention concerns a method of treating HIV infected patients said method comprising administering TMC278 or its stereoisomeric form or pharmaceutically acceptable salt or its prodrug, and a nucleotide reverse transcriptase inhibitor, in which method a therapeutically effective amount of TMC278 and the nucleotide reverse transcriptase inhibitor can be administered once daily.
- Still a further aspect of this invention comprises a method of treating HIV infected patients said method comprising administering TMC278 or its stereoisomeric form or pharmaceutically acceptable salt or its prodrug, in combination with a nucleoside reverse transcriptase inhibitor, and a nucleotide reverse transcriptase inhibitor, in which method a therapeutically effective amount of TMC278, the nucleotide reverse transcriptase inhibitor and the nucleoside reverse transcriptase inhibitor can be administered once daily.
- Still a further aspect of this invention comprises a method of treating HIV infected patients said method comprising administering TMC278 or its stereoisomeric form or pharmaceutically acceptable salt or its prodrug, in combination with a nucleoside reverse transcriptase inhibitor, and a second nucleoside reverse transcriptase inhibitor different from the former nucleoside reverse transcriptase inhibitor, in which method a therapeutically effective amount of TMC278, the nucleoside reverse transcriptase inhibitors can be administered once daily.
- The active ingredients in the methods of the invention are administered in therapeutically effective amounts, the latter meaning an amount that is sufficient to exert a sufficient HIV inhibitory effect during a certain time period, i.e. the time period between each intake of the formulations, preferably for about 24 hours.
- Particular embodiments are methods as specified above wherein one or more of the specific active ingredients mentioned herein such as emtricitabine, racemic FTC, lamivudin, tenofovir and its prodrug tenofovir disoproxil fumarate, are administered.
- One embodiment of the present invention relates to the present combinations for use as a medicine. Another embodiment relates to the combinations of the present invention for use in the manufacture of a medicament to treat HIV infected patients.
- Of particular interest are any of the combinations as specified herein, or any of the products, pharmaceutical formulations, unit dosage forms, methods and uses being based on said combinations, wherein TMC278 is E-TMC287, or preferably TMC278 hydrochloride salt or more preferably E-TMC278 hydrochloride salt.
- The combinations of this invention are especially useful for the treatment of AIDS and related clinical conditions such as AIDS related complex (ARC), progressive generalised lymphadenopathy (PGL) or AIDS related neurological conditions such as multiple sclerosis. The present triple combination may be particularly useful for the treatment of drug-naïve HIV infected patients.
- The combinations of the invention are also useful for the prevention of HIV transmission or infection in humans, in particular sexual transmission. Thus, the present invention relates to the use of combinations according to the present invention for the manufacture of a medicament for the prevention of HIV infection or transmission via sexual intercourse or related intimate contact between partners. The invention also relates to a method of preventing HIV infection or transmission via sexual intercourse or related intimate contact between partners comprising administering to a subject in need thereof an effective amount of any of the combinations according to the present invention.
- The respective daily dose for each of the active ingredients of a combination according to the present invention may range between 10 mg and 800 mg, preferably between 50 and 400 mg, more preferably between 50 and 300 mg, or between 100 and 300 mg. In particular, the daily dose for TMC278 may range between 10 mg and 500 mg, preferably between 10 and 300, more preferably between 50 and 250 mg, still more preferably between 50 and 200 mg, e.g. about 100 mg.
- The weight ratio of each couple of components of the triple combination taken on a daily basis may vary in a range from 1/10 to 10/1. Suitably, the weight ratio of each couple varies between 1/6 and 6/1, more suitably 1/4 and 4/1, preferably between 1/3 and 3/1, and more preferably between 1/2 and 2/1.
- Table 2 lists some examples of the daily dose for each of the active ingredients in combinations of compound E-TMC278, emtricitabine and tenofovir.
-
Combination no. E-TMC278 Emtricitabine Tenofovir 1 50 mg 200 mg — 2 50 mg — 300 mg 3 100 mg 200 mg — 4 100 mg — 300 mg 5 200 mg 200 mg — 6 200 mg — 300 mg 7 50 mg 200 mg 300 mg 8 100 mg 200 mg 300 mg 9 200 mg 200 mg 300 mg - Table 3 lists some examples of the daily dose for each of the active ingredients in combinations of TMC278, abacavir and lamivudine wherein the dose mentioned in the table for abacavir sulfate is the equivalent dose of abacavir base.
-
Combination Abacavir no. E-TMC278 Lamivudine sulfate 1 50 mg 150 mg 300 mg 2 100 mg 150 mg 300 mg 3 200 mg 150 mg 300 mg - Thus, an interesting combination according to the present invention comprises compound E-(A) in a daily dose ranging between 10 mg and 500 mg, a daily dose of 150 mg lamivudine and a daily dose of an equivalent of 300 mg abacavir base. Suitably, such combination is formulated in a single pharmaceutical form.
- Another interesting combination according to the present invention comprises compound E-(A) in a daily dose ranging between 50 mg and 250 mg, a daily dose of 150 mg lamivudine and a daily dose of an equivalent of 300 mg abacavir base. Suitably, such combination is formulated in a single pharmaceutical form.
- The present invention also relates to a pharmaceutical composition in a form adapted to be applied to a site where sexual intercourse or related intimate contact can take place, such as the genitals, rectum, mouth, hands, lower abdomen, upper thighs, especially the vagina and mouth, comprising a pharmaceutically acceptable carrier and as active ingredients an effective amount of a combination according to the present invention. As appropriate special adapted compositions there may be cited all compositions usually employed for being applied to the vagina, rectum, mouth and skin such as for example gels, jellies, creams, ointments, films, sponges, foams, intravaginal rings, cervical caps, suppositories for rectal or vaginal application, vaginal or rectal or buccal tablets, mouthwashes. To prepare such pharmaceutical compositions, an effective amount of each of the particular compounds of the triple combination as the active ingredients is combined in intimate admixture with a pharmaceutically acceptable carrier, which carrier may take a wide variety of forms depending on the form of administration. In order to increase the residence time of such pharmaceutical composition at the site of administration, it may be advantageous to include in the composition a bioadhesive, in particular a bioadhesive polymer. A bioadhesive may be defined as a material that adheres to a live biological surface such as for example a mucus membrane or skin tissue.
- Thus, the present invention also relates to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and as active ingredients an effective amount of each of the compounds of the present triple combination characterized in that the pharmaceutical composition is bioadhesive to the site of application. Preferably, the site of application is the vagina, rectum, mouth or skin, most preferred is the vagina.
- Otten R A et al in Journal of Virology (2000), 74(20), 9771-9775 and Witvrouw M et al in Antiviral Research (2000), 46(3), 215-221 disclose the ability of tenofovir to delay HIV viral breakthrough after high-risk sexual exposure.
- Pani A et al in Antiviral Chemistry & Chemotherapy (2001), 12(Suppl. 1), 51-59 describe the ability of lamivudine to delay viral breakthrough.
- The ability of TMC278 to prevent HIV infection via sexual intercourse or related intimate contact between partners can be demonstrated in the following test. Immature monocyte derived dendritic cells (immMO-DC) represent a good model for interstitial dendritic cells, which are early targets during sexual HIV transmission and important initiators of the immune response. These immMO-DC were used in “in vitro” models to test the prevention of HIV infection via sexual intercourse or related intimate contact between partners. One such model is described in the experimental part and indicates that the TMC278 potently inhibits HIV replication in MO-DC/CD4(+) T cell co-cultures.
- A double-blind, randomized, placebo-controlled Phase I trial was designed to evaluate safety, tolerability, and ex-vivo pharmacokinetics of single doses of compound E-TMC278 in healthy male volunteers. Oral doses of 12.5, 25, and 50 mg were formulated in PEG 400 and taken with a standard meal. The pharmacokinetic results are shown in Table 4.
- The pharmacokinetic results of another double-blind, randomized, placebo-controlled Phase I study with 4 dosing sessions to evaluate the safety, tolerability, pharmacokinetics and ex-vivo pharmacodynamics of single 100 mg and 200 mg oral doses of compound E-TMC278 in healthy male subjects are also reported in Table 4. Randomization was such that for each session 6 subjects received the same dose of compound E-TMC278 and 3 subjects received placebo. There was a time interval of about 14 days between each dosing session
- Table 4 shows that high and dose-proportional exposures were obtained. The correlation coefficient for the 5 Cmax datapoints is 0.9897 and for the area under the curve values between 0 and 48 hours (AUC0-48 hr) 0.9952. Half-life of plasma concentrations ranged between 37 and 39 hours. The compound was well tolerated by the volunteers. No relevant adverse effects of the drug were noted.
-
TABLE 4 Parameter 12.5 mg 25 mg 50 mg 100 mg 200 mg Cmax 73 ± 14 149 ± 32 267 ± 27 482 ± 121 807 ± 207 (ng/ml) Tmax (hr) 4.0 ± 0 4.0 ± 1.3 4.0 ± 1.3 4.3 ± 0.8 4.3 ± 0.8 AUG0-48hr 1337 ± 310 2805 ± 496 5094 ± 509 8162 ± 2251 15592 ± 2746 (nghr/ml) AUC0-∞ 2210 ± 473 4637 ± 1164 8872 ± 1342 15844 ± 4592 (nghr/ml) T1/2 (hr) 37.1 38.7 45 ± 9 55 ± 18 - Compound E-TMC278 was tested in a cell-based assay, using natural host cells of HIV. MT-4 cells (a cell line of human T cells) were infected with HIV-1 (wild type or mutants) and exposed to different concentrations of antiviral compound in the presence of 10% fetal calf serum. Cytotoxicity was determined in parallel with the antiviral activity so that the selectivity of the antiviral effect could be assessed. Active compounds have to penetrate the cell membrane in order to interfere with replication steps inside the cell.
- After four days of incubation at 37° C., the viability of the HIV and mock-infected cells was assessed by an automated tetrazolium-based colorimetric assay. This method enabled the calculation of both the 50% inhibitory concentration for inhibition of viral cytopathicity (IC50), the IC90, and the 50% cytotoxic concentration (CC50). The ratio CC50/IC50, also called the selectivity index, is an indication of the specificity of the antiviral effect. Tested HIV strains included: Wild type (wt) HIV-1; a panel of single and double mutants, obtained by site-directed mutagenesis (SDM), and a panel of clinical isolates, selected for resistance against NNRTIs.
- A limited panel of HIV-1 mutants was constructed using site-directed mutagenesis (SDM) and homologous recombination techniques. Compound E-TMC278 was tested against an extended panel of single and double mutants known to be resistant against commercially available NNRTIs. Nevirapine (NVP) and efavirenz (EFV) were included as controls.
- The results are shown in Table 5 (values presented are IC50 values in nM). For wild type virus, the obtained IC50 was 0.4 nM (0.15 ng/ml) and the IC90 1.3 nM (0.48 ng/ml). The HIV strain with the lowest sensitivity against compound E-TMC278 within this selection was the double mutant 100I+103N, with an IC50 of about 8 nM and an IC90 of about 16 nM.
-
TABLE 5 Compound NVP EFV E-TMC278 wild type 81 1.4 0.4 100I 597 35 0.4 101E 547 5 1.6 103N 2,879 28 0.3 106A 2,983 23 0.2 108I — 2 0.3 138K 64 1.3 0.4 179D 161 6 0.6 179E 158 5 0.4 181C 10,000 2 1.3 188C 3,764 5 0.1 188H 241 9 0.2 188L 10,000 78 2.0 190A 4,101 8 0.3 190S 10,000 275 0.1 225H 171 2 0.3 227C 1,816 36 2.0 227L 78 0.3 0.3 234I 45 NT 0.3 236L 41 1 0.3 100I + 103N 10,000 10,000 7.9 101E + 103N 7,033 84 0.5 103N + 181I 10,000 37 1.0 227L + 106A 10,000 8 1.0 - NNRTIs are highly selective inhibitors of HIV-1 but their current clinical use is limited by the rapid emergence of NNRTI (cross-) resistance. The rate of resistance emergence against compound E-TMC278 and the first generation NNRTIs nevirapine and efavirenz was compared in vitro.
- MT4 cells were infected with wild type HIV-1 at high multiplicity of infection (>1 infectious virus per cell, to maximize the genetic diversity of the virus population) in the presence of various concentrations of compound E-TMC278 (40, 200, 1000 and 5000×IC50), and were monitored twice a week for virus replication. Emerging virus was collected for pheno- and genotyping. Cultures without evidence of virus replication were further sub-cultivated in the presence of the same concentration of inhibitor for a total duration of 30 days (10 passages).
- Resistance to nevirapine emerged within 3-6 days, at all tested concentrations. Breakthrough virus harboured the typical Y181C mutation. The same experiments with efavirenz resulted in the selection of G190E at all concentrations (up to 5 μM) within 3 to 7 days. Compound E-TMC278 did not select for resistant virus within 30 days using wild-type virus. If a double resistant mutant K103N+Y181C (IC50 0.8 nM) was used instead of wild type virus, resistance did emerge at all tested concentrations. Starting from the single mutants Y181C (IC50 1.3 nM) or 103N (IC50 0.3 nM), virus breakthrough did not occur at 40 and 200 nM, but did occur at 10 nM.
- In this experimental setting of high genetic diversity, HIV-1, resistant to first generation NNRTIs, was selected very rapidly. Resistant viruses harboured only one mutation. In contrast, emergence of HIV-1, resistant to compound E-TMC278 was delayed or did not occur.
- Compound E-TMC278 had little or no effect on cardiovascular and pulmonary parameters in vivo at plasma levels covering and exceeding the targeted plasma levels in man and at concentrations in vitro covering or exceeding the anti-viral concentration in vitro.
- For instance, in one model, monocyte-derived dendritic cells (MO-DC) were infected for 2 hours with the monotropic HIV strain Ba-L at a multiplicity of infection (MOI) of 10-3. After infection, cells were washed 6 times and resuspended in 10% BCS at 400.000 cells/ml. Autologous CD4(+) T cells were purified out of the lymphocyte fraction of the same elutration as the MO-DC and used at a concentration of 2×106 cells/ml ((ratio MO-DC/CD4(+) T: 1/5).
- A serial dilution of a compound of formula (I) (test compound) was added to the MO-DC/CD4(+) T cell co-cultures. Each experiment was done in 96-well plates, in which each cup contained 50 μl of MO-DC, 50 μl of CD4(+) T cells and 100 μl of test compound. Half of the culture medium, with test compound, was refreshed twice weekly.
- Supernatants were analysed in ELISA after 14 days of culture. To determine antiviral activity, the test compound concentration able to suppress 50% of the viral replication at the end of the primary cultures (EC50) was measured. For compound E-TMC278, the EC50 value was 0.55 nM.
- Tablet formulation of the following composition:
-
Emtricitabine 300 mg Tenofovir diisoproxyl fumarate 300 mg E-TMC278 hydrochloride salt 110 mg HPMC 2910 15 mPa · s 24 mg Polysorbate 20 6 mg Crosspolyvidone 18 mg Lactose monohydrate 43 mg Magnesium stearate 3 mg Talcum 6 mg - The active ingredients and lactose are fluidised and sprayed with a solution of HPMC and polysorbate in water (at an equivalent of 120 ml/tablet). Subsequently crosspolyvidone is added, while still being fluidised, followed by magnesium stearate and talcum. The thus obtained granulate is compressed into 13 mm cylindrical tablets using standard compressing equipment.
Claims (21)
1. A combination comprising
4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]-amino]-2-pyrimidinyl]-amino]-benzonitrile, or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof;
a nucleoside reverse transcriptase inhibitor selected from emtricitabine, racemic FTC, lamivudine, abacavir, or a pharmaceutically acceptable salt thereof; and
a nucleotide reverse transcriptase inhibitor;
wherein the 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]-amino]-2-pyrimidinyl]-amino]-benzonitrile, the nucleotide reverse transcriptase inhibitor, and the nucleoside reverse transcriptase inhibitor are therapeutically effective HIV inhibitors at a dose that can be administered once daily.
2. The combination according to claim 1 , wherein the 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]-amino]-2-pyrimidinyl]-amino]-benzonitrile is E-4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]-amino]-2-pyrimidinyl]-amino]-benzonitrile.
3. The combination according to claim 1 , wherein the 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]-amino]-2-pyrimidinyl]-amino]-benzonitrile is E-4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]-amino]-2-pyrimidinyl]-amino]-benzonitrile hydrochloride.
4. The combination of claim 1 , wherein the nucleoside reverse transcriptase inhibitor is emtricitabine or a pharmaceutically acceptable salt thereof.
5. The combination according to claim 1 wherein the nucleoside reverse transcriptase inhibitor is racemic FTC or a pharmaceutically acceptable salt thereof.
6. The combination according to claim 1 wherein the nucleoside reverse transcriptase inhibitor is lamivudine or a pharmaceutically acceptable salt thereof.
7. The combination according to claim 1 wherein the nucleoside reverse transcriptase inhibitor is abacavir or a pharmaceutically acceptable salt thereof.
8. The combination according to claim 4 , wherein the 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]-amino]-2-pyrimidinyl]-amino]-benzonitrile is E-4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]-amino]-2-pyrimidinyl]-amino]-benzonitrile.
9. The combination according to claim 4 , wherein the 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]-amino]-2-pyrimidinyl]-amino]-benzonitrile is E-4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]-amino]-2-pyrimidinyl]-amino]-benzonitrile hydrochloride.
10. The combination according to claim 5 , wherein the 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]-amino]-2-pyrimidinyl]-amino]-benzonitrile is E-4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]-amino]-2-pyrimidinyl]-amino]-benzonitrile.
11. The combination according to claim 5 , wherein the 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]-amino]-2-pyrimidinyl]-amino]-benzonitrile is E-4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]-amino]-2-pyrimidinyl]-amino]-benzonitrile hydrochloride.
12. The combination according to claim 6 , wherein the 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]-amino]-2-pyrimidinyl]-amino]-benzonitrile is E-4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]-amino]-2-pyrimidinyl]-amino]-benzonitrile.
13. The combination according to claim 6 , wherein the 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]-amino]-2-pyrimidinyl]-amino]-benzonitrile is E-4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]-amino]-2-pyrimidinyl]-amino]-benzonitrile hydrochloride.
14. The combination according to claim 7 , wherein the 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]-amino]-2-pyrimidinyl]-amino]-benzonitrile is E-4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]-amino]-2-pyrimidinyl]-amino]-benzonitrile.
15. The combination according to claim 7 , wherein the 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]-amino]-2-pyrimidinyl]-amino]-benzonitrile is E-4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]-amino]-2-pyrimidinyl]-amino]-benzonitrile hydrochloride.
16. The combination according to claim 1 , wherein the weight ratio of each couple of components of the combination vary in a range of from 1/10 to 10/1.
17. A product containing a combination as claimed in claim 1 in a single unit dosage form.
18. A pharmaceutical formulation comprising a pharmaceutically acceptable carrier and a combination as claimed in claim 1 .
19. A kit comprising the combination of claim 1 packaged with instructions for use.
20. A method of treating HIV infection in a patient comprising administering to the patient a combination as claimed in claim 1 .
21. A pharmaceutical formulation comprising a pharmaceutically acceptable carrier and a combination as claimed in claim 4 .
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/472,870 US20220008417A1 (en) | 2003-09-03 | 2021-09-13 | Combinations of a pyrimidine containing nnrti with rt inhibitors |
Applications Claiming Priority (20)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US49977103P | 2003-09-03 | 2003-09-03 | |
EP03103275.8 | 2003-09-03 | ||
EP03103275 | 2003-09-03 | ||
EP03103319.4 | 2003-09-08 | ||
EP03103319 | 2003-09-08 | ||
EP03103335 | 2003-09-10 | ||
EP03103335.0 | 2003-09-10 | ||
EP03103668 | 2003-10-02 | ||
EP03103668.4 | 2003-10-02 | ||
US50848603P | 2003-10-03 | 2003-10-03 | |
PCT/EP2004/052028 WO2005021001A1 (en) | 2003-09-03 | 2004-09-03 | Combinations of a pyrimidine containing nnrti with rt inhibitors |
US57022806A | 2006-02-28 | 2006-02-28 | |
US12/574,881 US8841310B2 (en) | 2003-09-03 | 2009-10-07 | Combinations of a pyrimidine containing NNRTI with RT inhibitors |
US14/454,045 US20140349971A1 (en) | 2003-09-03 | 2014-08-07 | Combinations of A Pyrimidine Containing NNRTI with RT Inhibitors |
US14/744,501 US20150283135A1 (en) | 2003-09-03 | 2015-06-19 | Combinations Of A Pyrimidine Containing NNRTI With RT Inhibitors |
US15/383,076 US20170100398A1 (en) | 2003-09-03 | 2016-12-19 | Combinations of a pyrimidine containing nnrti with rt inhibitors |
US15/950,548 US20180228800A1 (en) | 2003-09-03 | 2018-04-11 | Combinations of a pyrimidine containing nnrti with rt inhibitors |
US16/360,693 US20190216807A1 (en) | 2003-09-03 | 2019-03-21 | Combinations of a pyrimidine containing nnrti with rt inhibitors |
US16/784,404 US20200171027A1 (en) | 2003-09-03 | 2020-02-07 | Combinations of a pyrimidine containing nnrti with rt inhibitors |
US17/472,870 US20220008417A1 (en) | 2003-09-03 | 2021-09-13 | Combinations of a pyrimidine containing nnrti with rt inhibitors |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/784,404 Continuation US20200171027A1 (en) | 2003-09-03 | 2020-02-07 | Combinations of a pyrimidine containing nnrti with rt inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
US20220008417A1 true US20220008417A1 (en) | 2022-01-13 |
Family
ID=34280181
Family Applications (9)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/570,228 Abandoned US20080200435A1 (en) | 2003-09-03 | 2004-09-03 | Combinations Of A Pyrimidine Containing Nnrti With Rt Inhibitors |
US12/574,881 Active 2025-12-09 US8841310B2 (en) | 2003-09-03 | 2009-10-07 | Combinations of a pyrimidine containing NNRTI with RT inhibitors |
US14/454,045 Abandoned US20140349971A1 (en) | 2003-09-03 | 2014-08-07 | Combinations of A Pyrimidine Containing NNRTI with RT Inhibitors |
US14/744,501 Abandoned US20150283135A1 (en) | 2003-09-03 | 2015-06-19 | Combinations Of A Pyrimidine Containing NNRTI With RT Inhibitors |
US15/383,076 Abandoned US20170100398A1 (en) | 2003-09-03 | 2016-12-19 | Combinations of a pyrimidine containing nnrti with rt inhibitors |
US15/950,548 Abandoned US20180228800A1 (en) | 2003-09-03 | 2018-04-11 | Combinations of a pyrimidine containing nnrti with rt inhibitors |
US16/360,693 Abandoned US20190216807A1 (en) | 2003-09-03 | 2019-03-21 | Combinations of a pyrimidine containing nnrti with rt inhibitors |
US16/784,404 Abandoned US20200171027A1 (en) | 2003-09-03 | 2020-02-07 | Combinations of a pyrimidine containing nnrti with rt inhibitors |
US17/472,870 Pending US20220008417A1 (en) | 2003-09-03 | 2021-09-13 | Combinations of a pyrimidine containing nnrti with rt inhibitors |
Family Applications Before (8)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/570,228 Abandoned US20080200435A1 (en) | 2003-09-03 | 2004-09-03 | Combinations Of A Pyrimidine Containing Nnrti With Rt Inhibitors |
US12/574,881 Active 2025-12-09 US8841310B2 (en) | 2003-09-03 | 2009-10-07 | Combinations of a pyrimidine containing NNRTI with RT inhibitors |
US14/454,045 Abandoned US20140349971A1 (en) | 2003-09-03 | 2014-08-07 | Combinations of A Pyrimidine Containing NNRTI with RT Inhibitors |
US14/744,501 Abandoned US20150283135A1 (en) | 2003-09-03 | 2015-06-19 | Combinations Of A Pyrimidine Containing NNRTI With RT Inhibitors |
US15/383,076 Abandoned US20170100398A1 (en) | 2003-09-03 | 2016-12-19 | Combinations of a pyrimidine containing nnrti with rt inhibitors |
US15/950,548 Abandoned US20180228800A1 (en) | 2003-09-03 | 2018-04-11 | Combinations of a pyrimidine containing nnrti with rt inhibitors |
US16/360,693 Abandoned US20190216807A1 (en) | 2003-09-03 | 2019-03-21 | Combinations of a pyrimidine containing nnrti with rt inhibitors |
US16/784,404 Abandoned US20200171027A1 (en) | 2003-09-03 | 2020-02-07 | Combinations of a pyrimidine containing nnrti with rt inhibitors |
Country Status (25)
Country | Link |
---|---|
US (9) | US20080200435A1 (en) |
EP (1) | EP1663240B2 (en) |
JP (3) | JP5507791B2 (en) |
KR (1) | KR20060090658A (en) |
CN (1) | CN101060844B (en) |
AP (1) | AP2109A (en) |
AU (5) | AU2004268390B2 (en) |
BE (1) | BE2015C053I2 (en) |
CA (1) | CA2537095C (en) |
CY (5) | CY2015039I1 (en) |
FI (1) | FI1663240T4 (en) |
FR (3) | FR15C0071I2 (en) |
HK (1) | HK1092698A1 (en) |
HR (1) | HRP20150798T4 (en) |
HU (5) | HUS1500053I1 (en) |
IL (2) | IL173438A (en) |
LT (2) | LTPA2016045I1 (en) |
LU (3) | LU92853I2 (en) |
MX (1) | MXPA06002437A (en) |
MY (1) | MY169670A (en) |
NL (2) | NL300781I2 (en) |
NO (5) | NO334877B1 (en) |
NZ (1) | NZ545306A (en) |
PL (1) | PL1663240T5 (en) |
WO (1) | WO2005021001A1 (en) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8101629B2 (en) | 2001-08-13 | 2012-01-24 | Janssen Pharmaceutica N.V. | Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile |
MY169670A (en) | 2003-09-03 | 2019-05-08 | Tibotec Pharm Ltd | Combinations of a pyrimidine containing nnrti with rt inhibitors |
JO3429B1 (en) | 2001-08-13 | 2019-10-20 | Janssen Pharmaceutica Nv | Hiv inhibiting pyrimidines derivatives |
US7638522B2 (en) | 2001-08-13 | 2009-12-29 | Janssen Pharmaceutica N.V. | Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile |
MXPA05001541A (en) | 2002-08-09 | 2005-04-19 | Janssen Pharmaceutica Nv | Processes for the preparation of 4-[[4-[[4 -(2-cyanoethenyl)-2, 6-dimethylphenyl] amino]-2 -pyrimidinyl] amino] benzonitrile. |
CA2512319A1 (en) | 2003-01-14 | 2004-08-05 | Gilead Sciences, Inc. | Compositions and methods for combination antiviral therapy |
WO2006024668A1 (en) * | 2004-09-02 | 2006-03-09 | Janssen Pharmaceutica N.V. | Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl] amino]benzonitrile |
CN101068597B (en) * | 2004-09-02 | 2012-04-18 | 詹森药业有限公司 | Fumarate of 4-((4-(4-(2-cyanoethenyl)-2,6-dimethylphenyl)amino)-2-pyrimidinyl)amino)benzonitrile |
EP1632232B3 (en) * | 2004-09-02 | 2022-03-30 | Janssen Pharmaceutica NV | Salt of 4[[4-[[4-(2-Cyanoethenyl)-2,6-dimethylphenyl]amino]-2-Pyrimidinyl]amino]benzonitrile |
MX2007002594A (en) * | 2004-09-02 | 2007-04-25 | Janssen Pharmaceutica Nv | Furamate of 4-( (4-( (4- (2-cyanoethenyl) -2, 6-dimethylphenyl) amino)-2 -pyrimidinyl) amino)benzonitrile. |
EP1789139B1 (en) * | 2004-09-02 | 2012-03-21 | Janssen Pharmaceutica NV | Fumarate of 4-((4-((4-(2-cyanoethenyl)-2,6-dimethylphenyl amino -2-pyrimidinyl amino benzonitrile |
TWI457136B (en) * | 2005-04-04 | 2014-10-21 | Tibotec Pharm Ltd | Prevention of hiv-infection |
TWI471145B (en) * | 2005-06-13 | 2015-02-01 | Bristol Myers Squibb & Gilead Sciences Llc | Unitary pharmaceutical dosage form |
TWI375560B (en) * | 2005-06-13 | 2012-11-01 | Gilead Sciences Inc | Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same |
RU2008128424A (en) * | 2005-12-14 | 2010-01-20 | Сипла Лимитед (In) | PHARMACEUTICAL COMBINATION, INCLUDING NUCLEOTID AND NUCLEOSIDE INVERSORS OF REVERSE TRANSCRIPTASE (SUCH AS TENOFOVIR AND LAMIVUDINES) IN VARIOUS DOSE PARTS |
TWI458483B (en) * | 2006-01-20 | 2014-11-01 | Tibotec Pharm Ltd | Long term treatment of hiv infection |
US9044509B2 (en) * | 2006-02-03 | 2015-06-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Inhibition of HIV infection through chemoprophylaxis |
FR2903312B1 (en) | 2006-07-05 | 2008-09-26 | Univ Aix Marseille Ii | USE OF INHIBITORS OF HMG-COA REDUCTASE AND FARNESYL-PYROPHOSPHATE SYNTHASE IN THE PREPARATION OF A MEDICINAL PRODUCT |
AR065720A1 (en) * | 2007-03-14 | 2009-06-24 | Tibotec Pharm Ltd | RECONSTITUTION POWERS THAT INCLUDE RILPIVIRINE DISPERSED IN CERTAIN POLYMERS. USE. PROCESS. |
JP5570999B2 (en) | 2008-01-03 | 2014-08-13 | ユニベルシテ デ―マルセイユ | Composition for use in anti-HIV therapy |
BRPI0923161B1 (en) * | 2008-12-24 | 2019-01-15 | Janssen R&D Ireland | one-piece implantable device containing rilpivirine |
BR112012015114B1 (en) | 2009-12-21 | 2023-01-10 | Janssen Sciences Ireland Uc | DEGRADABLE REMOVABLE SUBCUTANEOUS PHARMACEUTICAL IMPLANT FOR SUSTAINED RELEASE OF AN ACTIVE COMPOUND |
EP3351249A1 (en) | 2010-01-27 | 2018-07-25 | VIIV Healthcare Company | Antiviral therapy |
EP2826466A1 (en) * | 2010-11-19 | 2015-01-21 | Gilead Sciences, Inc. | Therapeutic compositions comprising rilpivirin hcl and tenofovir disoproxil fumarate |
WO2012125993A1 (en) | 2011-03-17 | 2012-09-20 | Teva Pharmaceutical Industries Ltd. | Solid state forms of rilpivirine base, and rilipivirine salts |
WO2013038425A1 (en) * | 2011-09-16 | 2013-03-21 | Hetero Research Foundation | Rilpivirine hydrochloride |
SI3608325T1 (en) | 2012-12-21 | 2022-09-30 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
JP6621933B2 (en) | 2015-11-09 | 2019-12-18 | ギリアード サイエンシス インコーポレーテッド | Therapeutic composition for treating human immunodeficiency virus |
KR20190073450A (en) | 2016-10-24 | 2019-06-26 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | Dispersible composition |
WO2018119371A1 (en) * | 2016-12-23 | 2018-06-28 | Temple University - Of The Commonwealth System Of Higher Education | Anti-flaviviridae activity of anti-retroviral non-nucleoside (nnrtis) and nucleoside reverse transcriptase inhibitors (nnrtis) |
US11234981B2 (en) | 2017-04-18 | 2022-02-01 | Cipla Limited | Combination therapy for use in treating retroviral infections |
WO2019021319A1 (en) * | 2017-07-27 | 2019-01-31 | Cipla Limited | Pharmaceutical compositions |
CN115397422A (en) | 2019-11-29 | 2022-11-25 | 西皮欧生命科学有限公司 | Compositions comprising rilpivirine and their use for treating tumors or cancers |
Family Cites Families (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5182111A (en) * | 1987-11-17 | 1993-01-26 | Boston University Research Foundation | In vivo delivery of active factors by co-cultured cell implants |
US5047407A (en) | 1989-02-08 | 1991-09-10 | Iaf Biochem International, Inc. | 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties |
GB8815265D0 (en) | 1988-06-27 | 1988-08-03 | Wellcome Found | Therapeutic nucleosides |
US5368864A (en) * | 1988-11-25 | 1994-11-29 | Henning Berlin Gmbh Chemie- Und Pharmawerk | Formulation of oxypurinol and/or its alkali and alkaline earth salts |
MY104575A (en) | 1989-12-22 | 1994-04-30 | The Wellcome Foundation Ltd | Therapeutic nucleosides. |
WO1992001453A1 (en) | 1990-07-19 | 1992-02-06 | Otsuka Pharmaceutical Co., Ltd. | Solid preparation |
US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
AU3124793A (en) * | 1991-10-29 | 1993-06-07 | Clover Consolidated, Limited | Crosslinkable polysaccharides, polycations and lipids useful for encapsulation and drug release |
DK0639971T3 (en) | 1992-05-13 | 2000-03-20 | Wellcome Found | Therapeutic combinations |
JPH06316524A (en) | 1992-09-11 | 1994-11-15 | Naoyuki Inoue | Anti-aids virus agent |
TW401303B (en) | 1994-07-01 | 2000-08-11 | Janssen Pharmaceutica Nv | Anti-HIV triple combination |
IT1281502B1 (en) * | 1995-06-13 | 1998-02-18 | Sardinian Antiviral Research C | USE OF A NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR IN COMBINATION WITH NUCLEOSIDE INHIBITORS FOR THE TREATMENT OF |
US6045829A (en) * | 1997-02-13 | 2000-04-04 | Elan Pharma International Limited | Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers |
ATE296091T1 (en) | 1999-09-21 | 2005-06-15 | Skyepharma Canada Inc | SURFACE-MODIFIED PARTICLE COMPOSITIONS OF BIOLOGICALLY ACTIVE SUBSTANCES |
US6743446B2 (en) * | 1999-12-15 | 2004-06-01 | The Ohio State University Research Foundation | Methods for stabilizing biologically active agents encapsulated in biodegradable controlled-release polymers |
TW200800298A (en) * | 2000-01-27 | 2008-01-01 | Zentaris Ag | Compressed microparticles for dry injection |
SK12822002A3 (en) | 2000-03-30 | 2003-02-04 | Bristol-Myers Squibb Company | Sustained release beadlets containing stavudine |
US20040115268A1 (en) * | 2000-04-26 | 2004-06-17 | Control Delivery Systems, Inc. | Systemic delivery of antiviral agents |
DE10050199A1 (en) | 2000-10-11 | 2002-04-25 | Ethicon Gmbh | Areal implant having a flexible basic structure on a polymer basis, contains ultrasonically detectable elements, which contain or produce gas and set up for detectability for at least four weeks after implantation |
US20040058956A1 (en) | 2000-12-11 | 2004-03-25 | Yohko Akiyama | Pharmaceutical composition having an improved water solubility |
ATE444060T1 (en) | 2001-06-22 | 2009-10-15 | Pfizer Prod Inc | PHARMACEUTICAL COMPOSITIONS CONTAINING DISPERSIONS OF MEDICINAL SUBSTANCES AND NEUTRAL POLYMERS |
JO3429B1 (en) * | 2001-08-13 | 2019-10-20 | Janssen Pharmaceutica Nv | Hiv inhibiting pyrimidines derivatives |
MY169670A (en) | 2003-09-03 | 2019-05-08 | Tibotec Pharm Ltd | Combinations of a pyrimidine containing nnrti with rt inhibitors |
WO2003043586A2 (en) | 2001-11-20 | 2003-05-30 | Advanced Inhalation Research, Inc. | Compositions for sustained action product delivery |
MXPA05001541A (en) | 2002-08-09 | 2005-04-19 | Janssen Pharmaceutica Nv | Processes for the preparation of 4-[[4-[[4 -(2-cyanoethenyl)-2, 6-dimethylphenyl] amino]-2 -pyrimidinyl] amino] benzonitrile. |
WO2004022033A1 (en) * | 2002-09-04 | 2004-03-18 | Microchips, Inc. | Method and device for the controlled delivery of parathyroid hormone |
AU2003291457A1 (en) | 2002-11-08 | 2004-06-03 | Glaxo Group Limited | Pharmaceutical antiviral compositions |
AP1927A (en) | 2002-11-15 | 2008-12-10 | Tibotec Pharm Ltd | Substituted indolepyridinium as anti-infective compounds |
AU2002350719A1 (en) | 2002-11-29 | 2004-06-23 | Janssen Pharmaceutica N.V. | Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base |
WO2004069812A1 (en) | 2003-02-07 | 2004-08-19 | Janssen Pharmaceutica N.V. | Pyrimidine derivatives for the prevention of hiv infection |
KR100629771B1 (en) * | 2004-01-27 | 2006-09-28 | 씨제이 주식회사 | Process for preparing oltipraz with diminished crystalline state or amorphous state |
AU2005253957B2 (en) | 2004-06-08 | 2011-08-25 | Janssen Pharmaceutica Nv | Pharmaceutical compositions |
MY191349A (en) | 2004-08-27 | 2022-06-17 | Bayer Pharmaceuticals Corp | New pharmaceutical compositions for the treatment of hyper-proliferative disorders |
WO2006024668A1 (en) | 2004-09-02 | 2006-03-09 | Janssen Pharmaceutica N.V. | Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl] amino]benzonitrile |
EP1632232B3 (en) | 2004-09-02 | 2022-03-30 | Janssen Pharmaceutica NV | Salt of 4[[4-[[4-(2-Cyanoethenyl)-2,6-dimethylphenyl]amino]-2-Pyrimidinyl]amino]benzonitrile |
KR20130030305A (en) | 2004-11-16 | 2013-03-26 | 엘란 파마 인터내셔널 리미티드 | Injectable nanoparticulate olanzapine formulations |
TWI457136B (en) | 2005-04-04 | 2014-10-21 | Tibotec Pharm Ltd | Prevention of hiv-infection |
TW200710091A (en) | 2005-04-11 | 2007-03-16 | Tibotec Pharm Ltd | (1,10B-dihydro-2-(aminoalkyl-phenyl)-5H-pyrazolo [1,5-c][1,3]benzoxazin-5-yl)phenyl methanone derivatives as HIV viral replication inhibitors |
JP2008538754A (en) * | 2005-04-11 | 2008-11-06 | ザ・ボード・オブ・トラスティーズ・オブ・ザ・レランド・スタンフォード・ジュニア・ユニバーシティ | Multilayer structure having a predetermined layer pattern containing a drug |
WO2006131806A2 (en) | 2005-06-07 | 2006-12-14 | Pfizer Products Inc. | Multiparticulates comprising low-solubility drugs and carriers that result in rapid drug release |
US10532028B2 (en) | 2005-07-28 | 2020-01-14 | Isp Investments Llc | Method to improve characteristics of spray dried powders and granulated materials, and the products thereby produced |
TWI458483B (en) | 2006-01-20 | 2014-11-01 | Tibotec Pharm Ltd | Long term treatment of hiv infection |
CA2654115C (en) | 2006-06-23 | 2015-12-22 | Tibotec Pharmaceuticals Ltd. | Aqueous suspensions of tmc278 |
US20080081064A1 (en) * | 2006-09-28 | 2008-04-03 | Surmodics, Inc. | Implantable Medical Device with Apertures for Delivery of Bioactive Agents |
AR065720A1 (en) | 2007-03-14 | 2009-06-24 | Tibotec Pharm Ltd | RECONSTITUTION POWERS THAT INCLUDE RILPIVIRINE DISPERSED IN CERTAIN POLYMERS. USE. PROCESS. |
ES2437331T3 (en) | 2007-07-12 | 2014-01-10 | Janssen R&D Ireland | Crystalline form of 4 - [[4 - [[4- (2-cyanoetenyl) -2,6-dimethylphenyl] amino] -2-pyrimidinyl] amino] benzonitrile |
WO2009046299A2 (en) | 2007-10-04 | 2009-04-09 | Boston Scientific Scimed, Inc | Implantable drug depot for intrathecal drug delivery system for pain management |
EP2358198A4 (en) * | 2008-10-24 | 2012-11-14 | Concert Pharmaceuticals Inc | Hydroxyethylamino sulfonamide derivatives |
-
2004
- 2004-09-02 MY MYPI20043578A patent/MY169670A/en unknown
- 2004-09-03 WO PCT/EP2004/052028 patent/WO2005021001A1/en active Application Filing
- 2004-09-03 US US10/570,228 patent/US20080200435A1/en not_active Abandoned
- 2004-09-03 PL PL04787096.9T patent/PL1663240T5/en unknown
- 2004-09-03 MX MXPA06002437A patent/MXPA06002437A/en active IP Right Grant
- 2004-09-03 KR KR1020067003074A patent/KR20060090658A/en active Search and Examination
- 2004-09-03 NZ NZ545306A patent/NZ545306A/en unknown
- 2004-09-03 EP EP04787096.9A patent/EP1663240B2/en active Active
- 2004-09-03 AP AP2006003551A patent/AP2109A/en active
- 2004-09-03 CA CA2537095A patent/CA2537095C/en active Active
- 2004-09-03 AU AU2004268390A patent/AU2004268390B2/en active Active
- 2004-09-03 CN CN2004800254267A patent/CN101060844B/en active Active
- 2004-09-03 JP JP2006525150A patent/JP5507791B2/en active Active
-
2006
- 2006-01-30 IL IL173438A patent/IL173438A/en active Protection Beyond IP Right Term
- 2006-03-27 NO NO20061374A patent/NO334877B1/en active Protection Beyond IP Right Term
- 2006-12-05 HK HK06113340.4A patent/HK1092698A1/en active IP Right Maintenance
-
2009
- 2009-10-07 US US12/574,881 patent/US8841310B2/en active Active
-
2011
- 2011-03-14 AU AU2011201123A patent/AU2011201123B2/en active Active
- 2011-05-24 IL IL213104A patent/IL213104A/en active IP Right Grant
- 2011-10-12 JP JP2011224982A patent/JP2012051915A/en not_active Withdrawn
-
2014
- 2014-06-26 AU AU2014203484A patent/AU2014203484B2/en active Active
- 2014-08-07 US US14/454,045 patent/US20140349971A1/en not_active Abandoned
- 2014-10-31 JP JP2014222770A patent/JP5820045B2/en active Active
- 2014-12-18 NO NO2014030C patent/NO2014030I1/en unknown
- 2014-12-18 NO NO2014031C patent/NO2014031I1/en not_active IP Right Cessation
- 2014-12-18 NO NO2014032C patent/NO2014032I1/en unknown
-
2015
- 2015-06-19 US US14/744,501 patent/US20150283135A1/en not_active Abandoned
- 2015-07-20 HR HRP20150798TT patent/HRP20150798T4/en unknown
- 2015-10-20 NL NL300781C patent/NL300781I2/nl unknown
- 2015-10-20 LU LU92853C patent/LU92853I2/en unknown
- 2015-10-21 HU HUS1500053C patent/HUS1500053I1/en unknown
- 2015-10-21 CY CY2015039C patent/CY2015039I1/en unknown
- 2015-10-21 HU HUS1500054C patent/HUS1500054I1/en unknown
- 2015-10-21 FR FR15C0071C patent/FR15C0071I2/en active Active
- 2015-10-21 CY CY2015040C patent/CY2015040I1/en unknown
- 2015-10-21 NL NL300768C patent/NL300768I2/en unknown
- 2015-10-21 HU HUS1500052C patent/HUS1500052I1/en unknown
- 2015-10-21 FR FR15C0073C patent/FR15C0073I2/en active Active
- 2015-10-21 FR FR15C0072C patent/FR15C0072I2/en active Active
- 2015-10-21 BE BE2015C053C patent/BE2015C053I2/fr unknown
- 2015-10-21 CY CY2015038C patent/CY2015038I2/en unknown
- 2015-10-21 LU LU92855C patent/LU92855I2/en unknown
- 2015-10-21 LU LU92854C patent/LU92854I2/en unknown
-
2016
- 2016-08-05 AU AU2016210733A patent/AU2016210733B2/en active Active
- 2016-12-19 US US15/383,076 patent/US20170100398A1/en not_active Abandoned
- 2016-12-20 LT LTPA2016045C patent/LTPA2016045I1/en unknown
- 2016-12-20 CY CY2016049C patent/CY2016049I1/en unknown
- 2016-12-20 CY CY2016048C patent/CY2016048I2/en unknown
- 2016-12-20 LT LTPA2015035C patent/LTC1663240I2/en unknown
- 2016-12-20 HU HUS1600059C patent/HUS1600059I1/en unknown
- 2016-12-20 FI FIEP04787096.9T patent/FI1663240T4/en active
- 2016-12-20 HU HUS1600058C patent/HUS1600058I1/en unknown
- 2016-12-20 NO NO2016025C patent/NO2016025I1/no unknown
-
2018
- 2018-04-11 US US15/950,548 patent/US20180228800A1/en not_active Abandoned
-
2019
- 2019-02-06 AU AU2019200813A patent/AU2019200813A1/en not_active Abandoned
- 2019-03-21 US US16/360,693 patent/US20190216807A1/en not_active Abandoned
-
2020
- 2020-02-07 US US16/784,404 patent/US20200171027A1/en not_active Abandoned
-
2021
- 2021-09-13 US US17/472,870 patent/US20220008417A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220008417A1 (en) | Combinations of a pyrimidine containing nnrti with rt inhibitors | |
KR101524165B1 (en) | Methods for improving the pharmacokinetics of hiv integrase inhibitors | |
DK1663240T3 (en) | COMBINATIONS OF A PYRIMIDINE-CONTAINING NNRTI WITH RT INHIBITORS | |
ZA200601820B (en) | Combinations of a pyrimidine containing NNRTI with RT inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
AS | Assignment |
Owner name: JANSSEN SCIENCES IRELAND UNLIMITED COMPANY, IRELAND Free format text: CHANGE OF NAME;ASSIGNOR:JANSSEN SCIENCES IRELAND UC;REEL/FRAME:060989/0661 Effective date: 20181004 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |